Attached files

file filename
EX-32.1 - EX-32.1 - IMS HEALTH INCa09-31060_1ex32d1.htm
EX-31.2 - EX-31.2 - IMS HEALTH INCa09-31060_1ex31d2.htm
EX-31.1 - EX-31.1 - IMS HEALTH INCa09-31060_1ex31d1.htm

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2009

 

OR

 

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from           to        

 

Commission File Number: 001-14049

 

 

IMS Health Incorporated

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

06-1506026

(State of Incorporation)

 

(I.R.S. Employer Identification No.)

 

901 Main Avenue, Norwalk, CT 06851

(Address of principal executive offices)(Zip Code)

 

(203) 845-5200

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days.  x Yes o No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  o Yes o No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer x

 

Accelerated Filer o

 

 

 

Non-Accelerated Filer o

 

Smaller Reporting Company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  o Yes x No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.  At September 30, 2009, there were 182,441,209 shares of IMS Health Incorporated Common Stock, $0.01 par value, outstanding.

 

 

 



Table of Contents

 

IMS HEALTH INCORPORATED

 

INDEX TO FORM 10-Q

 

 

PAGE(S)

PART I. FINANCIAL INFORMATION

 

 

 

Item 1. Financial Statements (Unaudited)

 

 

 

Condensed Consolidated Statements of Financial Position

 

 

 

As of September 30, 2009 and December 31, 2008

3

 

 

Condensed Consolidated Statements of Income

 

 

 

Three Months Ended September 30, 2009 and 2008

4

 

 

Nine Months Ended September 30, 2009 and 2008

5

 

 

Condensed Consolidated Statements of Cash Flows

 

 

 

Nine Months Ended September 30, 2009 and 2008

6

 

 

Condensed Consolidated Statements of Shareholders’ Deficit

 

 

 

Twelve Months Ended December 31, 2008 and

 

 

 

Nine Months Ended September 30, 2009

7

 

 

Notes to Condensed Consolidated Financial Statements

8 – 30

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

31 – 53

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

54

 

 

Item 4. Controls and Procedures

54

 

 

PART II. OTHER INFORMATION

 

 

 

Item 1. Legal Proceedings

55

 

 

Item 1A. Risk Factors

55 – 56

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

56

 

 

Item 6. Exhibits

57

 

 

SIGNATURES

58

 

 

EXHIBITS

59

 

2



Table of Contents

 

PART I. FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

 

IMS HEALTH INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited)

(Dollars and shares in thousands, except per share data)

 

 

 

As of September 30,
2009

 

As of December 31,
2008

 

Assets:

 

 

 

 

 

Current Assets:

 

 

 

 

 

Cash and cash equivalents

 

$

301,711

 

$

215,682

 

Accounts receivable, net of allowances of $10,107 and $5,960 in 2009 and 2008, respectively

 

309,136

 

382,776

 

Other current assets

 

185,714

 

174,099

 

Total Current Assets

 

796,561

 

772,557

 

Securities and other investments

 

7,503

 

7,121

 

Property, plant and equipment, net of accumulated depreciation of $238,067 and $208,340 in 2009 and 2008, respectively

 

179,313

 

183,055

 

Computer software

 

250,234

 

253,583

 

Goodwill (Note 6)

 

699,531

 

663,532

 

Other assets

 

177,383

 

207,289

 

Total Assets

 

$

2,110,525

 

$

2,087,137

 

 

 

 

 

 

 

Liabilities, Redeemable Noncontrolling Interest and Shareholders’ Deficit:

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

Accounts payable

 

$

95,326

 

$

119,798

 

Accrued and other current liabilities

 

364,421

 

275,764

 

Accrued income taxes

 

 

47,735

 

Short-term deferred tax liability

 

2,796

 

9,444

 

Deferred revenues

 

103,162

 

88,484

 

Total Current Liabilities

 

565,705

 

541,225

 

Postretirement and postemployment benefits

 

111,275

 

109,516

 

Long-term debt (Note 9)

 

1,344,850

 

1,404,199

 

Other liabilities

 

131,373

 

185,677

 

Total Liabilities

 

$

2,153,203

 

$

2,240,617

 

 

 

 

 

 

 

Commitments and Contingencies (Note 7)

 

 

 

 

 

 

 

 

 

 

 

Redeemable Noncontrolling Interest (Note 13)

 

$

 

$

100,000

 

 

 

 

 

 

 

Shareholders’ Deficit:

 

 

 

 

 

Common Stock, par value $.01, authorized 800,000 shares; issued 335,045 shares in 2009 and 2008, respectively

 

$

3,350

 

$

3,350

 

Capital in excess of par

 

538,488

 

546,478

 

Retained earnings

 

3,231,111

 

3,060,345

 

Treasury stock, at cost, 152,604 and 153,564 shares in 2009 and 2008, respectively

 

(3,554,173

)

(3,576,446

)

Cumulative translation adjustment

 

(151,959

)

(171,990

)

Unamortized postretirement and postemployment balances

 

(111,050

)

(117,111

)

Total IMS Health Shareholders’ Deficit

 

$

(44,233

)

$

(255,374

)

Noncontrolling Interests (Note 13)

 

$

1,555

 

$

1,894

 

Total Deficit

 

$

(42,678

)

$

(253,480

)

Total Liabilities, Redeemable Noncontrolling Interest and Shareholders’ Deficit

 

$

2,110,525

 

$

2,087,137

 

 

See accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited).

 

3



Table of Contents

 

IMS HEALTH INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

(Dollars and shares in thousands, except per share data)

 

 

 

Three Months Ended
September 30,

 

 

 

2009

 

2008

 

 

 

 

 

 

 

Information and analytics revenue

 

$

425,197

 

$

445,654

 

Consulting and services revenue

 

115,574

 

128,061

 

Operating Revenue

 

540,771

 

573,715

 

 

 

 

 

 

 

Operating costs of information and analytics

 

181,974

 

190,139

 

Direct and incremental costs of consulting and services

 

58,774

 

62,185

 

External-use software amortization

 

9,823

 

12,291

 

Selling and administrative expenses

 

166,885

 

161,878

 

Depreciation and other amortization

 

24,558

 

23,246

 

Severance, impairment and other charges (Note 15)

 

104,301

 

 

Operating (Loss) Income

 

(5,544

)

123,976

 

 

 

 

 

 

 

Interest income

 

183

 

3,107

 

Interest expense

 

(8,961

)

(12,119

)

(Loss) gains from investments, net

 

(618

)

379

 

Other expense, net

 

(7,793

)

(2,981

)

Non-Operating Loss, Net

 

(17,189

)

(11,614

)

 

 

 

 

 

 

(Loss) income before provision for income taxes

 

(22,733

)

112,362

 

Benefit (provision) for income taxes (Note 11)

 

13,474

 

(35,049

)

Net (Loss) Income

 

$

(9,259

)

$

77,313

 

Less: Net income attributable to noncontrolling interests (Note 13)

 

41

 

1,401

 

Net (Loss) Income Attributable to IMS Health

 

$

(9,300

)

$

75,912

 

 

 

 

 

 

 

Basic (Loss) Earnings Per Share of Common Stock

 

$

(0.05

)

$

0.42

 

Diluted (Loss) Earnings Per Share of Common Stock

 

$

(0.05

)

$

0.41

 

 

 

 

 

 

 

Weighted average number of shares outstanding – Basic

 

182,536

 

182,157

 

Dilutive effect of shares issuable as of period-end under stock-based compensation plans and other

 

186

 

956

 

Adjustment of shares outstanding applicable to exercised and cancelled stock options during the period

 

31

 

8

 

Weighted Average Number of Shares Outstanding – Diluted

 

182,753

 

183,121

 

 

See accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited).

 

4



Table of Contents

 

IMS HEALTH INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

(Dollars and shares in thousands, except per share data)

 

 

 

Nine Months Ended
September 30,

 

 

 

2009

 

2008

 

 

 

 

 

 

 

Information and analytics revenue

 

$

1,253,885

 

$

1,355,281

 

Consulting and services revenue

 

336,670

 

393,323

 

Operating Revenue

 

1,590,555

 

1,748,604

 

 

 

 

 

 

 

Operating costs of information and analytics

 

528,213

 

576,514

 

Direct and incremental costs of consulting and services

 

176,931

 

202,641

 

External-use software amortization

 

30,464

 

38,048

 

Selling and administrative expenses

 

490,211

 

493,010

 

Depreciation and other amortization

 

70,399

 

66,656

 

Severance, impairment and other charges (Note 15)

 

129,729

 

 

Operating Income

 

164,608

 

371,735

 

 

 

 

 

 

 

Interest income

 

1,666

 

8,682

 

Interest expense

 

(27,491

)

(35,352

)

(Loss) gains from investments, net

 

(581

)

379

 

Other income (expense), net

 

1,588

 

(27,762

)

Non-Operating Loss, Net

 

(24,818

)

(54,053

)

 

 

 

 

 

 

Income before provision for income taxes

 

139,790

 

317,682

 

Benefit (provision) for income taxes (Note 11)

 

49,121

 

(100,833

)

Net Income

 

$

188,911

 

$

216,849

 

Less: Net income attributable to noncontrolling interests (Note 13)

 

1,994

 

4,067

 

Net Income Attributable to IMS Health

 

$

186,917

 

$

212,782

 

 

 

 

 

 

 

Basic Earnings Per Share of Common Stock

 

$

1.03

 

$

1.16

 

Diluted Earnings Per Share of Common Stock

 

$

1.02

 

$

1.16

 

 

 

 

 

 

 

Weighted average number of shares outstanding – Basic

 

182,255

 

183,145

 

Dilutive effect of shares issuable as of period-end under stock-based compensation plans and other

 

88

 

1,022

 

Adjustment of shares outstanding applicable to exercised and cancelled stock options during the period

 

34

 

36

 

Weighted Average Number of Shares Outstanding – Diluted

 

182,377

 

184,203

 

 

See accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited).

 

5



Table of Contents

 

IMS HEALTH INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(Dollars in thousands)

 

 

 

Nine Months Ended September 30,

 

 

 

2009

 

2008

 

Cash Flows from Operating Activities:

 

 

 

 

 

Net income

 

$

188,911

 

$

216,849

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

100,863

 

104,704

 

Bad debt expense

 

3,673

 

1,685

 

Deferred income taxes

 

(24,187

)

1,033

 

(Loss) gains from investments, net

 

581

 

(379

)

Non-cash stock-based compensation charges

 

24,312

 

22,052

 

Non-cash portion of severance, impairment and other charges

 

18,248

 

 

Net tax benefit on stock-based compensation

 

(4,632

)

(296

)

Excess tax benefits from stock-based compensation

 

 

(94

)

Change in assets and liabilities, excluding effects from acquisitions and dispositions:

 

 

 

 

 

Net decrease in accounts receivable

 

64,579

 

21,479

 

Net decrease (increase) in work-in-process inventory

 

2,733

 

(1,027

)

Net increase in prepaid expenses and other current assets

 

(3,459

)

(12,859

)

Net decrease in accounts payable

 

(26,357

)

(26,807

)

Net decrease in accrued and other current liabilities

 

(57

)

(11,443

)

Net increase (decrease) in accrued severance, impairment and other charges

 

93,514

 

(38,623

)

Net increase (decrease) in deferred revenues

 

13,549

 

(35,383

)

Net (decrease) increase in accrued income taxes

 

(115,331

)

5,951

 

Net decrease in pension assets (net of liabilities)

 

8,266

 

3,103

 

Net decrease in other long-term assets (net of long-term liabilities)

 

2,328

 

2,617

 

Net Cash Provided by Operating Activities

 

347,534

 

252,562

 

Cash Flows Used in Investing Activities:

 

 

 

 

 

Capital expenditures

 

(17,093

)

(30,782

)

Additions to computer software

 

(59,582

)

(51,280

)

Proceeds from sale of assets, net

 

713

 

1,392

 

Proceeds from sale of investments, net

 

38

 

379

 

Payments for acquisitions of businesses, net of cash acquired

 

(3,419

)

(50,395

)

Funding of venture capital investments

 

(1,000

)

(1,700

)

Other investing activities, net

 

690

 

(3,821

)

Net Cash Used in Investing Activities

 

(79,653

)

(136,207

)

Cash Flows Used in Financing Activities:

 

 

 

 

 

Net (decrease) increase in revolving credit facility and other

 

(66,821

)

56,164

 

Proceeds from private placement notes

 

 

240,000

 

Repayment of private placement notes

 

 

(150,000

)

Payments for purchase of treasury stock

 

 

(230,433

)

Proceeds from exercise of stock options

 

 

5,520

 

Excess tax benefits from stock-based compensation

 

 

94

 

Dividends paid

 

(16,151

)

(16,626

)

Proceeds from employee stock purchase plan and other

 

 

(25

)

Decrease in cash overdrafts

 

(5,443

)

(1,876

)

Payments to noncontrolling interests and other financing activities

 

(103,875

)

(5,072

)

Net Cash Used in Financing Activities

 

(192,290

)

(102,254

)

Effect of Exchange Rate Changes on Cash and Cash Equivalents

 

10,438

 

(3,162

)

Increase in Cash and Cash Equivalents

 

86,029

 

10,939

 

Cash and Cash Equivalents, Beginning of Period

 

215,682

 

218,249

 

Cash and Cash Equivalents, End of Period

 

$

301,711

 

$

229,188

 

 

See accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited).

 

6



Table of Contents

 

IMS HEALTH INCORPORATED

 

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ DEFICIT (Unaudited)

(Dollars and shares in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated Other Comprehensive Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Post

 

 

 

Total

 

 

 

 

 

 

 

Shares

 

 

 

Capital

 

 

 

 

 

Cumulative

 

Retirement

 

Other

 

IMS Health

 

 

 

 

 

 

 

Common

 

Treasury

 

Common

 

in Excess

 

Retained

 

Treasury

 

Translation

 

Post Employ

 

Comprehensive

 

Shareholders’

 

Noncontrolling

 

Total

 

 

 

Stock

 

Stock

 

Stock

 

of Par

 

Earnings

 

Stock

 

Adjustment

 

Adjust

 

Income

 

(Deficit) Equity

 

Interest

 

(Deficit) Equity

 

Balance, December 31, 2007

 

335,045

 

143,818

 

$

3,350

 

$

535,500

 

$

2,771,278

 

$

(3,355,790

)

$

61,931

 

$

(56,584

)

 

 

$

(40,315

)

$

1,444

 

$

(38,871

)

Net Income Attributable to IMS Health

 

 

 

 

 

 

 

 

 

311,250

 

 

 

 

 

 

 

$

311,250

 

311,250

 

940

 

312,190

 

Cash Dividends ($0.12 per share)

 

 

 

 

 

 

 

 

 

(22,183

)

 

 

 

 

 

 

 

 

(22,183

)

 

 

(22,183

)

Stock-Based Compensation Expense

 

 

 

 

 

 

 

28,036

 

 

 

 

 

 

 

 

 

 

 

28,036

 

 

 

28,036

 

Net Tax Benefit on Stock-Based Compensation

 

 

 

 

 

 

 

(499

)

 

 

 

 

 

 

 

 

 

 

(499

)

 

 

(499

)

Treasury Shares Acquired Under Purchases

 

 

 

10,495

 

 

 

 

 

 

 

(238,046

)

 

 

 

 

 

 

(238,046

)

 

 

(238,046

)

Treasury Shares Reissued Under:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Stock Options

 

 

 

(277

)

 

 

(920

)

 

 

6,441

 

 

 

 

 

 

 

5,521

 

 

 

5,521

 

Vesting of Restricted Stock

 

 

 

(473

)

 

 

(15,642

)

 

 

10,977

 

 

 

 

 

 

 

(4,665

)

 

 

(4,665

)

Employee Stock Purchase Plan

 

 

 

1

 

 

 

3

 

 

 

(28

)

 

 

 

 

 

 

(25

)

 

 

(25

)

Cumulative Translation Adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

(233,921

)

 

 

(233,921

)

(233,921

)

(490

)

(234,411

)

Postretirement and Postemployment Adjustments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(60,527

)

(60,527

)

(60,527

)

 

 

(60,527

)

Total Comprehensive Income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

16,802

 

 

 

450

 

 

 

Balance, December 31, 2008

 

335,045

 

153,564

 

$

3,350

 

$

546,478

 

$

3,060,345

 

$

(3,576,446

)

$

(171,990

)

$

(117,111

)

 

 

$

(255,374

)

$

1,894

 

$

(253,480

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income Attributable to IMS Health

 

 

 

 

 

 

 

 

 

186,917

 

 

 

 

 

 

 

$

186,917

 

186,917

 

106

 

187,023

 

Cash Dividends ($0.12 per share)

 

 

 

 

 

 

 

 

 

(16,151

)

 

 

 

 

 

 

 

 

(16,151

)

 

 

(16,151

)

Stock-Based Compensation Expense

 

 

 

 

 

 

 

25,350

 

 

 

 

 

 

 

 

 

 

 

25,350

 

 

 

25,350

 

Net Tax Benefit on Stock-Based Compensation

 

 

 

 

 

 

 

(4,632

)

 

 

 

 

 

 

 

 

 

 

(4,632

)

 

 

(4,632

)

Treasury Shares Reissued Under:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of Restricted Stock

 

 

 

(960

)

 

 

(28,708

)

 

 

22,273

 

 

 

 

 

 

 

(6,435

)

 

 

(6,435

)

Cumulative Translation Adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

20,031

 

 

 

20,031

 

20,031

 

(445

)

19,586

 

Postretirement and Postemployment Adjustments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,061

 

6,061

 

6,061

 

 

 

6,061

 

Total Comprehensive Income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

213,009

 

 

 

(339

)

 

 

Balance, September 30, 2009

 

335,045

 

152,604

 

$

3,350

 

$

538,488

 

$

3,231,111

 

$

(3,554,173

)

$

(151,959

)

$

(111,050

)

 

 

$

(44,233

)

$

1,555

 

$

(42,678

)

 

See accompanying Notes to the Condensed Consolidated Financial Statements (Unaudited).

 

7



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

Note 1.  Interim Condensed Consolidated Financial Statements (Unaudited)

 

The accompanying Condensed Consolidated Financial Statements (Unaudited) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and Article 10 of Regulation S-X under the Securities and Exchange Act of 1934, as amended.  The Condensed Consolidated Financial Statements (Unaudited) do not include all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements.  In the opinion of management, all adjustments, all of which are of a normal recurring nature, considered necessary for a fair presentation of the statements of financial position, income, shareholders’ deficit and cash flows for the periods presented have been included. The results of operations for interim periods are not necessarily indicative of the results expected for the full year. The December 31, 2008 balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America.  The Condensed Consolidated Financial Statements (Unaudited) and related notes should be read in conjunction with the Consolidated Financial Statements and related notes of IMS Health Incorporated (the “Company” or “IMS”) included in its 2008 Annual Report on Form 10-K.  The Company has evaluated for disclosure subsequent events that have occurred up to October 30, 2009, the date of issuance of these financial statements.  Certain prior year amounts have been reclassified to conform to the 2009 presentation.  Amounts presented in the Condensed Consolidated Financial Statements (Unaudited) may not add due to rounding.

 

Note 2.  Basis of Presentation

 

IMS Health Incorporated is the leading global provider of market intelligence to the pharmaceutical and healthcare industries. The Company offers leading-edge market intelligence products and services that are integral to its clients’ day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. The Company’s information products are developed to meet client needs by using data secured from a worldwide network of suppliers in more than 100 countries. The Company’s business lines are:

 

·

Commercial Effectiveness to increase clients’ productivity across end-to-end sales, marketing, promotional and performance management processes;

 

 

·

Product and Portfolio Management to provide clients with insights into market measurement so they can optimize their product portfolio and strategies; and

 

 

·

New Business Areas that support pharmaceutical client business initiatives in managed markets, consumer health, and pricing and market access, and that also serve payer and government audiences.

 

Within these business lines, the Company provides consulting and services that use in-house capabilities and methodologies to assist clients in analyzing and evaluating market trends, strategies and tactics, and to help in the development and implementation of customized software applications and data warehouse tools.

 

8



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

The Company operates in more than 100 countries.

 

The Company is managed on a global business model with global leaders for the majority of its critical business processes and accordingly has one reportable segment (see Note 16).

 

Note 3.  Summary of Recent Accounting Pronouncements

 

In June 2009, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance codifying generally accepted accounting principles in the U.S. (“GAAP”).  This guidance was effective for financial statements issued for interim and annual periods ending after September 15, 2009.  The adoption of this authoritative guidance did not have a material impact on the financial results of the Company.

 

In September 2006, the FASB issued authoritative guidance defining fair value, establishing a framework for measuring fair value under GAAP, and expanding disclosures about fair value measurements. This guidance was effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years.  The adoption of this authoritative guidance did not have a material impact on the financial results of the Company.  In February 2008, the FASB issued authoritative guidance which delayed the effective date of its previously issued fair value guidance for one year for certain non-financial assets and liabilities and removed certain leasing transactions from its scope.  The adoption of this authoritative guidance did not have a material impact on the financial results of the Company.

 

In December 2008, the FASB issued authoritative guidance on an employer’s disclosures about plan assets of a defined benefit pension or other postretirement plan.  This guidance is effective for fiscal years ending after December 15, 2009, with earlier application permitted. Upon initial application, the provisions of this guidance are not required for earlier periods that are presented for comparative purposes.  The Company is currently evaluating the new disclosure requirements under this authoritative guidance.

 

In April 2009, the FASB issued authoritative guidance on determining fair values when there is no active market or where the price inputs being used represent distressed sales.  It also reaffirmed what previous guidance had stated is the objective of fair value measurement—to reflect how much an asset would be sold for in an orderly transaction (as opposed to a distressed or forced transaction) at the date of the financial statements under current market conditions.  This guidance was effective for interim and annual periods ending after September 15, 2009.  The adoption of this authoritative guidance did not have a material impact on the financial results of the Company.

 

In April 2009, the FASB issued authoritative guidance which required disclosures about fair value of financial instruments for interim reporting periods of publicly traded companies as well as in annual financial statements. This standard also required those disclosures in summarized financial information at interim reporting periods.  This guidance was effective for interim reporting periods ending after September 15, 2009.  The adoption of this authoritative guidance did not have a material impact on the financial results of the Company.

 

9



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

In May 2009, the FASB issued authoritative guidance establishing general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued or are available to be issued.  This guidance was effective for interim or annual financial periods ending after September, 15, 2009.  The adoption of this authoritative guidance did not have a material impact on the financial results of the Company.

 

In June 2009, the FASB issued authoritative guidance eliminating the concept of qualifying special-purpose entities (“QSPEs”), changing the requirements for derecognizing financial assets and requiring additional disclosures about transfers of financial assets, including securitization transactions, and an entity’s continuing involvement in and exposure to the risks related to transferred financial assets.  This guidance must be applied as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period and for interim and annual reporting periods thereafter. The adoption of this authoritative guidance is not expected to have a material impact on the financial results of the Company.

 

In June 2009, the FASB issued authoritative guidance eliminating the exemption for QSPEs, requiring a new approach for determining who should consolidate variable-interest entities (“VIEs”), and changing when it is necessary to reassess who should consolidate VIEs.  This guidance shall be effective as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter.  The adoption of this authoritative guidance is not expected to have a material impact on the financial results of the Company.

 

In October 2009, the FASB issued authoritative guidance revising the current accounting treatment to specifically address how to determine whether an arrangement involving multiple deliverables contains more than one unit of accounting. This guidance is applicable to revenue arrangements entered into or materially modified during the company’s first fiscal year that begins after June 15, 2010. The guidance may be applied either prospectively from the beginning of the fiscal year for new or materially modified arrangements or retrospectively. The Company is currently evaluating this authoritative guidance to determine any potential impact that it may have on the financial results of the Company.

 

In October 2009, the FASB issued authoritative guidance changing the accounting model for revenue arrangements that include both tangible products and software elements. Tangible products containing software components and non-software components that function together to deliver the tangible product’s essential functionality, are no longer within the scope of the software revenue guidance. This guidance is applicable to revenue arrangements entered into or materially modified during the company’s first fiscal year that begins after June 15, 2010. The guidance may be applied either prospectively from the beginning of the fiscal year for new or materially modified arrangements or retrospectively. The Company is currently evaluating this authoritative guidance to determine any potential impact that it may have on the financial results of the Company.

 

10



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

Note 4.  Summary of Significant Accounting Policies

 

Operating Costs of Information and Analytics

 

Operating costs of information and analytics (“I&A”) include costs of data, data processing and collection and costs attributable to personnel involved in production, data management and delivery of the Company’s I&A offerings.

 

One of the Company’s major expenditures is the cost for the data it receives from suppliers.  After receipt of the raw data and prior to the data being available for use in any part of its business, the Company is required to transform the raw data into useful information through a series of comprehensive processes.  These processes involve significant employee costs and data processing costs.

 

Costs associated with the Company’s data purchases are deferred within work-in-process inventory and recognized as expense as the corresponding data product revenue is recognized by the Company, generally over a thirty to sixty day period.

 

Direct and Incremental Costs of Consulting and Services

 

Direct and incremental costs of consulting and services (“C&S”) include the costs of the Company’s consulting staff directly involved with delivering revenue generating engagements, related accommodations and the costs of primary market research data purchased specifically for certain individual C&S engagements.  Although the Company’s data is used in multiple customer solutions across different offerings within both I&A and C&S, the Company does not have a meaningful way to allocate the direct cost of the data between I&A and C&S revenues.  As such, the direct and incremental costs of C&S do not reflect the total costs incurred to deliver its C&S revenues.

 

Costs associated with the Company’s time and material and fixed-price C&S contracts are recognized as incurred.

 

Note 5.  Acquisitions

 

The Company makes acquisitions in order to expand its products, services and geographic reach.  On January 1, 2009, the Company adopted authoritative guidance which established principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interest in the acquiree and the goodwill acquired.  The impact of the adoption of this authoritative guidance on the Company’s financial results will be dependent on the terms and conditions of acquisitions consummated on or after the adoption date.

 

During the nine months ended September 30, 2009, the Company did not complete any acquisitions.

 

11



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

During the nine months ended September 30, 2008, the Company completed four acquisitions of Robinson and James Research Pty Limited (Australia), Fourth Hurdle Consulting Limited (U.K.), Health Benchmarks, Inc. (U.S.) and RMBC Pharma Limited (Russia) at an aggregate cost of approximately $31,900 which were accounted for under the purchase method of accounting.  As such, the aggregate purchase price was allocated on a preliminary basis to the assets acquired based on estimated fair values as of the closing date.  The purchase price allocations were finalized during the first quarter of 2009 and during 2008. The Condensed Consolidated Financial Statements (Unaudited) include the results of these acquired companies subsequent to the closing of these acquisitions.  Had these acquisitions occurred as of January 1, 2008 or 2007, the impact on the Company’s results of operations would not have been significant. Goodwill of approximately $22,200 was recorded in connection with these acquisitions, of which $5,700 is deductible for tax purposes.

 

Note 6.  Goodwill and Intangible Assets

 

Goodwill and intangible assets that have indefinite useful lives are not amortized and are tested at least annually (or based on any triggering event) for impairment. The Company completed its annual impairment tests as of September 30, 2009 and 2008 and was not required to recognize any goodwill impairment charges. During the nine months ended September 30, 2009, the Company’s goodwill increased by $35,999 mainly due to foreign currency translation adjustments. During the nine months ended September 30, 2008, the Company’s goodwill increased by $24,501 mainly due to the preliminary allocation of purchase price for the acquisitions completed during the nine months ended September 30, 2008 (see Note 5).

 

Intangible assets that have finite useful lives are amortized. All of the Company’s other acquired intangibles are subject to amortization. Intangible asset amortization expense was $4,347 and $13,231 during the three and nine months ended September 30, 2009, respectively, and $4,814 and $14,303 during the three and nine months ended September 30, 2008, respectively.  At September 30, 2009, intangible assets were primarily composed of customer relationships, databases and trade names (principally included in other assets) and computer software.  The gross carrying amounts and related accumulated amortization of these intangibles were $188,397 and $111,866, respectively, at September 30, 2009 and $189,383 and $98,736, respectively, at December 31, 2008.  These intangibles are amortized over periods ranging from two to twenty years.  As of September 30, 2009, the weighted average amortization periods of the acquired intangibles by asset class are listed in the following table:

 

Intangible Asset Type

 

Weighted Average
Amortization Period (Years)

 

Customer Relationships

 

10.0

 

Computer Software and Algorithms

 

7.0

 

Databases

 

4.7

 

Trade Names

 

4.3

 

Other

 

4.0

 

Weighted average

 

8.8

 

 

12



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

Based on current estimated useful lives, amortization expense associated with intangible assets at September 30, 2009 is estimated to be approximately $4,060 for the remaining quarter in 2009.  Thereafter, annual amortization expense associated with intangible assets is estimated to be as follows:

 

Year Ended
December 31,

 

Amortization
Expense

 

2010

 

$

13,299

 

2011

 

11,963

 

2012

 

10,314

 

2013

 

10,036

 

2014

 

8,299

 

Thereafter

 

$

18,560

 

 

Note 7.  Contingencies

 

The Company and its subsidiaries are involved in legal and tax proceedings, claims and litigation arising in the ordinary course of business. Management periodically assesses the Company’s liabilities and contingencies in connection with these matters based upon the latest information available. For those matters where management currently believes it is probable that the Company will incur a loss and that the probable loss or range of loss can be reasonably estimated, the Company has recorded reserves in the Condensed Consolidated Financial Statements (Unaudited) based on its best estimates of such loss. In other instances, because of the uncertainties related to either the probable outcome or the amount or range of loss, management is unable to make a reasonable estimate of a liability, if any. However, even in many instances where the Company has recorded a reserve, the Company is unable to predict with certainty the final outcome of the matter or whether resolution of the matter will materially affect the Company’s results of operations, financial position or cash flows. As additional information becomes available, the Company adjusts its assessment and estimates of such liabilities accordingly.

 

The Company routinely enters into agreements with its suppliers to acquire data and with its customers to sell data, all in the normal course of business. In these agreements, the Company sometimes agrees to indemnify and hold harmless the other party for any damages such other party may suffer as a result of potential intellectual property infringement and other claims related to the use of the data. These indemnities typically have terms of approximately two years. The Company has not accrued a liability with respect to these matters, as the exposure is considered remote.

 

Based on its review of the latest information available, in the opinion of management, the ultimate liability of the Company in connection with pending tax and legal proceedings, claims and litigation will not have a material effect on the Company’s results of operations, cash flows or financial position, with the possible exception of the matters described below.

 

D&B Legacy and Related Tax Matters

 

Sharing Disputes. In 1996, the company then known as The Dun & Bradstreet Corporation (“D&B”) and now known as R.H. Donnelley Corporation (“Donnelley”) separated into three public

 

13



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

companies by spinning off ACNielsen Corporation (“ACNielsen”) and the company then known as Cognizant Corporation (“Cognizant”) (the “1996 Spin-Off”).  Cognizant is now known as Nielsen Media Research, Inc., a subsidiary of The Nielsen Company, formerly known as VNU N.V. (“NMR”).  The agreements effecting the 1996 Spin-Off allocated tax-related liability with respect to certain prior business transactions between D&B and Cognizant.  The D&B portion of such liability is now shared among Donnelley and certain of its former affiliates (the “Donnelley Parties”), and the Cognizant portion of such liability is shared between NMR and the Company pursuant to the agreements effecting Cognizant’s spin-off of the Company in 1998 (the “1998 Spin-Off”).

 

The underlying tax controversies with the Internal Revenue Service (“IRS”) have substantially all been resolved and the Company paid to the IRS the amounts that it believed were due and owing.  In the first quarter of 2006, Donnelley indicated that it disputed the amounts contributed by the Company toward the resolution of these matters based on the Donnelley Parties’ interpretation of the allocation of liability under the 1996 Spin-Off agreements. In August 2006, the Donnelley Parties commenced arbitration regarding one of these disputes (referred to herein as the “Dutch Partnership Dispute”).  The Dutch Partnership Dispute was resolved during the third quarter of 2008 when the parties consented to the entry of a consent award by the arbitration panel.  Pursuant to the terms of the consent award, in the third quarter of 2008, the Company made a payment of $4,600 ($3,100 net of tax benefit) and an additional interest and cost payment of $2,600 ($1,700 net of tax benefit) to the Donnelley Parties.  The remaining disputes were resolved during the second quarter of 2009 by agreement among the parties.  Pursuant to the 2009 settlement agreement, the Company made a payment of $10,750 ($8,000 net of tax benefit) to the Donnelley Parties in full satisfaction of its liability with respect to the remaining disputes (see Note 11).

 

The Partnership (Tax Year 1997). During the fourth quarter of 2008, the Company entered into a final agreement with the IRS in which the IRS disallowed certain items of partnership expense for tax year 1997 with respect to a partnership now substantially owned by the Company (the “Partnership”).  During 1997, the Partnership was substantially owned by Cognizant, but liability for this matter was allocated to the Company pursuant to the agreements effecting the 1998 Spin-Off.  Pursuant to the settlement, during the second quarter of 2009, the Company paid $20,400 (tax and interest, net of tax benefit) to the IRS in full satisfaction of its liability with respect to the Partnership for tax year 1997.

 

In addition to these matters, the Company and its predecessors have entered, and the Company continues to enter, into global tax planning initiatives in the normal course of their businesses.  These activities are subject to review by applicable tax authorities.  As a result of the review process, uncertainties exist and it is possible that some of these matters could be resolved adversely to the Company.

 

IMS Health Government Solutions Voluntary Disclosure Program Participation

 

The Company’s wholly-owned subsidiary, IMS Government Solutions Inc., is primarily engaged in providing services and products under contracts with the U.S. government.  U.S. government contracts are subject to extensive legal and regulatory requirements and, from time to time, agencies of the U.S. government have the ability to investigate whether contractors’ operations are being

 

14



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

conducted in accordance with such requirements.  U.S. government investigations, whether relating to these contracts or conducted for other reasons, could result in administrative, civil or criminal liabilities, including repayments, fines or penalties being imposed on us, or could lead to suspension or debarment from future U.S. government contracting.  U.S. government investigations often take years to complete and may result in no adverse action against the Company.

 

IMS Government Solutions discovered potential noncompliance with various contract clauses and requirements under its General Services Administration Contract which was awarded in 2002 to its predecessor company, Synchronous Knowledge Inc. (Synchronous Knowledge Inc. was acquired by IMS in May 2005).  Upon discovery of the potential noncompliance, the Company began remediation efforts, promptly disclosed the potential noncompliance to the U.S. government, and was accepted into the Department of Defense Voluntary Disclosure Program.  The Company filed its Voluntary Disclosure Program Report (“Disclosure Report”) on August 29, 2008.  Based on the Company’s findings as disclosed in the Disclosure Report, the Company recorded a reserve of approximately $3,700 for this matter in the third quarter of 2008.  The Company is currently unable to determine the outcome of this matter pending the resolution of the Voluntary Disclosure Program process and its ultimate liability arising from this matter could exceed its current reserve.

 

Other Contingencies

 

Contingent Consideration. Under the terms of certain purchase agreements related to acquisitions consummated in 2008 and prior, the Company may be required to pay additional amounts as contingent consideration based on the achievement of certain performance related targets during 2009. These additional payments will be recorded as either compensation expense or goodwill.  The Company paid approximately $2,400 under these contingencies during 2009. Based on current estimates, the Company expects that additional contingent consideration under these agreements may total approximately $3,200. It is expected that these contingencies will be resolved within a specified time period after the end of calendar year 2009.

 

15



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

Note 8.  Stock-Based Compensation

 

The following table summarizes activity of stock options for the periods indicated:

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

 

 

Exercise

 

 

 

 

 

Price Per

 

 

 

Shares

 

Share

 

Options Outstanding, December 31, 2006

 

21,396

 

$

23.43

 

Exercised

 

(6,299

)

$

22.72

 

Forfeited

 

(200

)

$

24.14

 

Cancelled

 

(371

)

$

27.61

 

Options Outstanding, December 31, 2007

 

14,526

 

$

23.62

 

Granted

 

1,159

 

$

22.58

 

Exercised

 

(277

)

$

19.91

 

Forfeited

 

(88

)

$

23.86

 

Cancelled

 

(2,141

)

$

25.51

 

Options Outstanding, December 31, 2008

 

13,179

 

$

23.29

 

Granted

 

1,795

 

$

13.43

 

Forfeited

 

(87

)

$

17.50

 

Cancelled

 

(3,323

)

$

26.68

 

Options Outstanding, September 30, 2009

 

11,564

 

$

20.83

 

Options Vested or Expected to Vest, September 30, 2009

 

11,349

 

$

20.92

 

Exercisable, September 30, 2009

 

9,092

 

$

22.06

 

 

The following table summarizes activity of restricted stock units (“RSUs”) with service conditions:

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

 

 

Grant Date

 

 

 

Shares

 

Fair Value

 

Unvested, December 31, 2006

 

1,558

 

$

25.04

 

Granted

 

1,219

 

$

29.64

 

Vested

 

(296

)

$

26.06

 

Forfeited

 

(148

)

$

28.09

 

Unvested, December 31, 2007

 

2,333

 

$

27.16

 

Granted

 

1,356

 

$

22.24

 

Vested

 

(569

)

$

27.45

 

Forfeited

 

(348

)

$

26.74

 

Unvested, December 31, 2008

 

2,772

 

$

24.75

 

Granted

 

2,100

 

$

13.43

 

Vested

 

(870

)

$

25.65

 

Forfeited

 

(183

)

$

23.29

 

Unvested, September 30, 2009

 

3,819

 

$

18.39

 

Vested or Expected to Vest, September 30, 2009

 

3,452

 

$

18.51

 

 

16



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

The following table summarizes activity of RSUs with performance conditions:

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

 

 

Grant Date

 

 

 

Shares

 

Fair Value

 

Unvested, December 31, 2006

 

613

 

$

24.20

 

Granted

 

402

 

$

14.72

 

Vested

 

(84

)

$

18.65

 

Forfeited

 

(6

)

$

27.00

 

Unvested, December 31, 2007

 

925

 

$

20.56

 

Granted

 

357

 

$

12.97

 

Vested

 

(109

)

$

23.86

 

Forfeited

 

(12

)

$

27.26

 

Unvested, December 31, 2008

 

1,161

 

$

17.84

 

Granted

 

675

 

$

13.78

 

Vested

 

(536

)

$

19.91

 

Forfeited

 

(40

)

$

14.63

 

Unvested, September 30, 2009

 

1,260

 

$

15.82

 

Vested or Expected to Vest, September 30, 2009

 

1,176

 

$

15.08

 

 

The following table summarizes activity of non-employee director deferred stock granted in lieu of board meeting fees:

 

 

 

 

 

Weighted

 

 

 

 

 

Average

 

 

 

 

 

Grant Date

 

 

 

Shares

 

Fair Value

 

Outstanding, December 31, 2006

 

33

 

$

22.49

 

Granted

 

5

 

$

29.50

 

Outstanding, December 31, 2007

 

38

 

$

23.37

 

Granted

 

6

 

$

19.71

 

Outstanding, December 31, 2008

 

44

 

$

22.81

 

Granted

 

6

 

$

13.80

 

Issued

 

(14

)

$

21.68

 

Outstanding, September 30, 2009

 

36

 

$

21.71

 

 

The following table summarizes the components and classification of stock-based compensation expense for the periods indicated:

 

17



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2009

 

2008

 

2009

 

2008

 

Stock Options

 

$

1,190

 

$

424

 

$

2,369

 

$

3,641

 

RSUs

 

8,554

 

5,401

 

22,981

 

18,413

 

Employee Stock Purchase Plan

 

 

 

 

(2

)

Total Stock-Based Compensation Expense

 

$

9,744

 

$

5,825

 

$

25,350

 

$

22,052

 

 

 

 

 

 

 

 

 

 

 

Operating Costs of I&A

 

$

669

 

$

679

 

$

1,906

 

$

2,300

 

Direct and Incremental Costs of C&S

 

1,194

 

948

 

3,348

 

2,659

 

Selling and Administrative Expenses

 

6,843

 

4,198

 

19,058

 

17,093

 

Severance, Impairment and Other Charges (Note 15)

 

1,038

 

 

1,038

 

 

Total Stock-Based Compensation Expense

 

$

9,744

 

$

5,825

 

$

25,350

 

$

22,052

 

 

 

 

 

 

 

 

 

 

 

Tax Benefit on Stock-Based Compensation Expense

 

$

3,055

 

$

1,911

 

$

8,009

 

$

7,038

 

 

 

 

 

 

 

 

 

 

 

Capitalized Stock-Based Compensation Expense

 

$

52

 

$

49

 

$

135

 

$

155

 

 

For a complete description of the Company’s Stock Incentive Plans and its accounting policies regarding stock-based compensation, refer to Notes 2 and 11 of the Company’s 2008 Annual Report on Form 10-K as filed with the SEC.

 

Note 9.  Financial Instruments

 

On January 1, 2009, the Company adopted authoritative guidance which requires enhanced disclosures about an entity’s derivative and hedging activities as provided below. As this authoritative guidance requires only additional disclosures, the adoption of it did not have an impact on the Company’s financial results.

 

Foreign Exchange Risk Management

 

The Company transacts business in more than 100 countries and is subject to risks associated with changing foreign exchange rates. The Company’s objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes. Accordingly, the Company enters into foreign currency forward contracts to minimize the impact of foreign exchange movements on net income, non-U.S. Dollar anticipated royalties, and on the value of non-functional currency assets and liabilities.

 

It is the Company’s policy to enter into foreign currency transactions only to the extent necessary to meet its objectives as stated above. The Company does not enter into foreign currency transactions

 

18



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

for investment or speculative purposes. The principal currencies hedged are the Euro, the Japanese Yen, the British Pound, the Swiss Franc and the Canadian Dollar.

 

The impact of foreign exchange risk management activities on pre-tax income for the three and nine months ended September 30, 2009 were net losses of $7,694 and net gains of $1,727, respectively, and net losses of $2,934 and $27,662 for the three and nine months ended September 30, 2008, respectively.

 

At September 30, 2009, the Company had assets of approximately $528,182 and liabilities of approximately $542,835 in foreign exchange forward contracts outstanding with various expiration dates through September 2010 relating to non-US Dollar net income, non-U.S. Dollar anticipated royalties and non-functional currency assets and liabilities (see below). Foreign exchange forward contracts are recorded at estimated fair value. The estimated fair values of the forward contracts are based on quoted market prices.

 

Unrealized and realized gains and losses on the contracts hedging net income and non-functional currency assets and liabilities do not qualify for hedge accounting, and therefore are not deferred and are included in the Consolidated Statements of Income in Other income (expense), net.

 

Unrealized gains and losses on the contracts hedging non-U.S. Dollar anticipated royalties qualify for hedge accounting, and are therefore deferred and included in OCI “Other Comprehensive Income.”

 

 

 

Fair Value of Derivative Instruments (1)

 

 

 

Asset Derivatives

 

Liability Derivatives

 

 

 

As of
September 30,
2009

 

As of
December 31,
2008

 

As of
September 30,
2009

 

As of
December 31,
2008

 

Derivatives designated as hedging instruments

 

 

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

$

180,589

 

$

172,113

 

$

192,191

 

$

179,110

 

Derivatives not designated as hedging instruments

 

 

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

347,593

 

236,977

 

350,644

 

238,023

 

Total Derivatives

 

$

528,182

 

$

409,090

 

$

542,835

 

$

417,133

 

 


(1) The net amounts of these derivatives are included in Current Assets and Current Liabilities in the Condensed Consolidated Statements of Financial Position (Unaudited).

 

19



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

 

Effect of Derivatives on Financial Performance for the Three Months Ended September 30,

 

Derivatives in Cash
Flow Hedging

 

Amount of
Gain/(Loss)
Recognized in OCI
on Derivatives

 

Location of Gain/(Loss)
Reclassified from OCI

 

Amount of
Gain/(Loss) from
OCI into Income

 

Relationships

 

2009

 

2008

 

into Income

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

$

(10,200

)

$

1,500

 

Other Income (Expense), Net

 

$

(700

)

$

(3,600

)

 

Effect of Derivatives on Financial Performance for the Nine Months Ended September 30,

 

Derivatives in Cash
Flow Hedging

 

Amount of
Gain/(Loss)
Recognized in OCI
on Derivatives

 

Location of Gain/(Loss)
Reclassified from OCI

 

Amount of
Gain/(Loss) from
OCI into Income

 

Relationships

 

2009

 

2008

 

into Income

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

$

(3,900

)

$

(6,100

)

Other Income (Expense), Net

 

$

700

 

$

(11,800

)

 

Fair Value Disclosures

 

At September 30, 2009, the Company’s financial instruments included cash, cash equivalents, and receivables, accounts payable and long-term debt. At September 30, 2009, the fair values of cash, cash equivalents, receivables and accounts payable approximated carrying values due to the short-term nature of these instruments. At September 30, 2009, the fair value of long-term debt approximated carrying value.

 

Effective January 1, 2008, the Company adopted authoritative guidance which established a three-level hierarchy for disclosure of fair value measurements as follows:

 

Level 1 –

Quoted prices in active markets for identical assets or liabilities.

Level 2 –

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3 –

Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

 

The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated:

 

 

 

Basis of Fair Value Measurements

 

 

 

September 30, 2009

 

 

 

Level 1

 

Level 2

 

Level 3

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

Derivatives (1)

 

$

 

$

528,182

 

$

 

$

528,182

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

Derivatives (1)

 

$

 

$

542,835

 

$

 

$

542,835

 

 

20



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

 

 

December 31, 2008

 

Assets

 

 

 

 

 

 

 

 

 

Derivatives (1)

 

$

 

$

409,090

 

$

 

$

409,090

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

Derivatives (1)

 

$

 

$

417,133

 

$

 

$

417,133

 

 


(1)  Derivatives consist of foreign exchange contracts based on observable market inputs of spot and forward rates.

 

Credit Concentrations

 

The Company continually monitors its positions with, and the credit quality of, the financial institutions which are counterparties to its financial instruments and does not anticipate non-performance by the counterparties. The Company would not realize a material loss as of September 30, 2009 in the event of non-performance by any one counterparty.  In general, the Company enters into transactions only with financial institution counterparties that have a credit rating of A or better. In addition, the Company limits the amount of credit exposure with any one institution.

 

The Company maintains accounts receivable balances ($309,136 and $382,776, net of allowances, at September 30, 2009 and December 31, 2008, respectively), principally from customers in the pharmaceutical industry. The Company’s trade receivables do not represent significant concentrations of credit risk at September 30, 2009 due to the credit worthiness of its customers and their dispersion across many geographic areas.

 

Lines of Credit

 

The following table summarizes the Company’s long-term debt at September 30, 2009 and December 31, 2008:

 

 

 

2009

 

2008

 

5.58% Private Placement Notes, principal payment of $105,000 due January 2015

 

$

105,000

 

$

105,000

 

5.99% Private Placement Notes, principal payment of $135,000 due January 2018

 

135,000

 

135,000

 

5.55% Private Placement Notes, principal payment of $150,000 due April 2016

 

150,000

 

150,000

 

1.70% Private Placement Notes, principal payment of 34,395,000 Japanese Yen due January 2013

 

385,164

 

381,304

 

Revolving Credit Facility:

 

 

 

 

 

Japanese Yen denominated borrowings at average floating rates of approximately 0.78%

 

360,686

 

435,895

 

U.S. Dollar denominated borrowings at average floating rates of approximately 0.65%

 

159,000

 

147,000

 

Bank Term Loan, principal payment of $50,000 due June 2011 at average floating rate of approximately 0.59%

 

50,000

 

50,000

 

Total Long-Term Debt

 

$

1,344,850

 

$

1,404,199

 

 

In February 2008, the Company closed a private placement transaction pursuant to which it issued $105,000 of seven-year debt at a fixed rate of 5.58%, and $135,000 of ten-year debt at a fixed rate of 5.99% to several highly rated insurance companies.  The Company used the proceeds for share

 

21



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

repurchases (see Note 12) and to refinance existing debt.

 

In July 2006, the Company entered into a $1,000,000 revolving credit facility with a syndicate of 12 banks (“Revolving Credit Facility”) replacing its existing $700,000 facility.  The terms of the Revolving Credit Facility extended the maturity of the facility in its entirety to a term of five years, maturing July 2011, reduced the borrowing margins, and increased subsidiary borrowing limits.  Total borrowings under the Revolving Credit Facility were $519,686 and $582,895 at September 30, 2009 and December 31, 2008, respectively, all of which were classified as long-term.  The Company defines long-term lines as those where the lines are non-cancellable for more than 365 days from the balance sheet date by the financial institutions except for specified, objectively measurable violations of the provisions of the agreement.  In general, rates for borrowing under the Revolving Credit Facility are LIBOR plus 40 basis points and can vary based on the Company’s Debt to EBITDA ratio.  The weighted average interest rates for the Company’s lines were 0.74% and 1.36% at September 30, 2009 and December 31, 2008, respectively.  In addition, the Company is required to pay a commitment fee on any unused portion of the facilities of 0.01%.  At September 30, 2009, the Company had approximately $480,314 available under existing bank credit facilities.

 

In June 2006, the Company closed a $50,000 three-year term loan with a bank.  The term loan allows the Company to borrow at a floating rate with a lower borrowing margin than the Company’s revolving credit facility.  The term loan also provides the Company with two one-year options to extend the term at the Company’s discretion.  In August 2008, the Company exercised the first one-year option to extend the term through June 2010, and in June 2009 the Company exercised the second one-year option to extend the term through June 2011. The Company used the proceeds to refinance existing debt borrowed under the revolving credit facility.

 

In April 2006, the Company closed a private placement transaction pursuant to which it issued $150,000 of ten-year notes to two highly rated insurance companies at a fixed rate of 5.55%.  The Company used the proceeds to refinance existing debt of $150,000 drawn under a short term credit agreement with a bank in January 2006.

 

In January 2006, the Company closed a private placement transaction pursuant to which its Japanese subsidiary issued 34,395,000 Japanese Yen seven-year debt (equal to $300,000 at date of issuance) to several highly rated insurance companies at a fixed rate of 1.70%. The Company used the proceeds to refinance existing debt in Japan.

 

The Company’s financing arrangements provide for certain covenants and events of default customary for similar instruments, including in the case of its main bank arrangements, the private placement transactions, and the term loan, covenants to maintain specific ratios of consolidated total indebtedness to EBITDA and of EBITDA to certain fixed charges.  At September 30, 2009, the Company was in compliance with these financial debt covenants.

 

22



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

Note 10.  Pension and Postretirement Benefits

 

The following table provides the Company’s expense associated with pension and postretirement benefits.  For a complete description of the Company’s pension and postretirement benefits, refer to Note 10 of the Company’s 2008 Annual Report on Form 10-K as filed with the SEC.

 

Components of Net Periodic Benefit Cost for the

 

Pension Benefits

 

Other Benefits

 

Three Months Ended September 30,

 

2009

 

2008

 

2009

 

2008

 

Service cost

 

$

3,338

 

$

3,761

 

$

 

$

 

Interest cost

 

4,834

 

5,094

 

180

 

191

 

Expected return on plan assets

 

(6,181

)

(7,765

)

 

 

Amortization of prior service (credit) cost

 

(28

)

2

 

(41

)

(123

)

Amortization of net loss

 

2,329

 

782

 

206

 

155

 

Curtailment charge

 

 

 

 

292

 

Net periodic benefit cost

 

$

4,292

 

$

1,874

 

$

345

 

$

515

 

 

Components of Net Periodic Benefit Cost for the

 

Pension Benefits

 

Other Benefits

 

Nine Months Ended September 30,

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

Service cost

 

$

10,059

 

$

12,376

 

$

 

$

 

Interest cost

 

14,278

 

15,374

 

540

 

575

 

Expected return on plan assets

 

(18,111

)

(23,623

)

 

 

Amortization of prior service (credit) cost

 

(86

)

14

 

(123

)

(129

)

Amortization of net loss

 

7,057

 

2,046

 

492

 

446

 

Curtailment charge

 

 

 

 

292

 

Settlement credit

 

(8

)

 

 

 

Net periodic benefit cost

 

$

13,189

 

$

6,187

 

$

909

 

$

1,184

 

 

Note 11.  Income Taxes

 

The Company operates in more than 100 countries around the world and its earnings are taxed at the applicable income tax rate in each of these countries.

 

For the three months ended September 30, 2009, the Company’s effective tax rate was reduced by the expiration of certain statutes of limitation (tax benefits of $14,100). For the nine months ended September 30, 2009, the Company’s effective tax rate was reduced as a result of the expiration of certain statutes of limitation (tax benefits of $14,100), the reorganization of certain subsidiaries which resulted in a foreign exchange loss recognized for tax purposes (tax benefit of $63,200), the settlement of a certain state tax matter (tax benefit of $16,300), the resolution of certain legacy tax matters (tax benefit of $9,500) (see Note 7, “Sharing Disputes.”) and the repayment of a certain intercompany loan which resulted in a foreign exchange loss recognized for tax purposes (tax benefit of $6,100).  For the three months ended September 30, 2008, the Company’s effective rate was reduced by the resolution of a certain legacy tax matter (tax benefit

 

23



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

of $5,900).  For the nine months ended September 30, 2008, the Company’s effective tax rate was reduced by the resolution of a certain legacy tax matter (tax benefit of $5,900), by the result of audit settlements with taxing authorities (tax benefit of $10,300), and the result of filing an advance pricing agreement (“APA”) between two taxing jurisdictions (tax benefit of $4,900).  The APA ensures conformity between the jurisdictions’ taxing authorities regarding the treatment of certain intercompany transactions, thereby allowing the Company to record a corresponding tax benefit.  Also during this period, the Company recorded tax expense for tax positions related to non-US transactions offset by a benefit related to the expiration of certain statutes of limitation (net tax expense of $4,300).

 

For the three and nine months ended September 30, 2009, the Company recorded $5,300 and $12,500, respectively, of tax expense related to unrecognized tax benefits that if recognized, would favorably affect the effective tax rate.  Interest and penalties of $800 and $3,300, respectively, are included in these amounts. For the three and nine months ended September 30, 2008, the Company recorded $5,200 and $15,200, respectively, of tax expense related to unrecognized tax benefits including $2,500 and $7,800, respectively, of interest and penalties.

 

The Company files numerous consolidated and separate income tax returns in U.S. (federal and state) and non-U.S. jurisdictions.  The Company is no longer subject to U.S. federal income tax examination by tax authorities for years before 2006. The Company is no longer subject to state and local income tax examination by tax authorities for years before 1997.  Further, with few exceptions, the Company is no longer subject to examination by tax authorities in its material non-U.S. jurisdictions prior to 2004.  It is reasonably possible that within the next twelve months the Company could realize $26,700 of unrecognized tax benefits as a result of the expiration of certain statutes of limitation.

 

Note 12.  IMS Health Capital Stock

 

The Company’s share repurchase program has been developed to buy opportunistically, when the Company believes that its share price provides it with an attractive use of its cash flow and debt capacity.

 

On December 18, 2007, the Board of Directors authorized a stock repurchase program to buy up to 20,000 shares. As of September 30, 2009, 9,505 shares remained available for repurchase under the December 2007 program.

 

During the nine months ended September 30, 2009, the Company did not repurchase any shares of outstanding Common Stock under this program.

 

During the nine months ended September 30, 2008, the Company repurchased 10,055 shares of outstanding Common Stock under this program at a total cost of $230,433.

 

These share repurchases positively impacted the Company’s diluted earnings per share by $0.01 and $0.03 for the three and nine months ended September 30, 2008, respectively.

 

Shares acquired through the Company’s repurchase programs described above are open-market purchases or privately negotiated transactions in compliance with SEC Rule 10b-18.

 

24



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

Under the Company’s Restated Certificate of Incorporation as amended, the Company has authority to issue 820,000 shares with a par value of $.01 per share of which 800,000 represent shares of Common Stock, 10,000 represent shares of preferred stock and 10,000 represent shares of Series Common Stock.  The preferred stock and Series Common Stock can be issued with varying terms, as determined by the Board of Directors.

 

Note 13.  Noncontrolling Interests

 

On January 1, 2009, the Company adopted authoritative guidance which established accounting and reporting standards pertaining to ownership interests in subsidiaries held by parties other than the parent, the amount of net income attributable to the parent and to the noncontrolling interests, changes in a parent’s ownership interests, and the valuation of any retained noncontrolling equity investment when a subsidiary is deconsolidated.  This guidance also established disclosure requirements that identify and distinguish between the interests of the parent and the interests of the noncontrolling owners.  The adoption of this authoritative guidance resulted in the reclassification of amounts previously referred to as minority interests and currently referred to as noncontrolling interests, from mezzanine equity (between Total Liabilities and Shareholders’ Deficit) to a separate component of Shareholders’ Deficit in the Company’s Condensed Consolidated Statements of Financial Position (Unaudited).  Additionally, net income attributable to noncontrolling interests, which previously was included in Other expense, net on a pretax basis, is shown separately from net income attributable to the Company in the Company’s Condensed Consolidated Statements of Income (Unaudited).  The adoption of this authoritative guidance did not have a material impact on the Company’s financial results.

 

The following table reconciles noncontrolling interests included as a separate component of Shareholders’ Deficit.  Prior year amounts have been reclassified to conform to the current year presentation.

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2009

 

2008

 

2009

 

2008

 

Noncontrolling interests, beginning of period

 

$

1,462

 

$

1,984

 

$

1,894

 

$

1,444

 

Income attributable to noncontrolling interests

 

41

 

302

 

106

 

770

 

Translation adjustments attributable to noncontrolling interests

 

52

 

(348

)

(445

)

(276

)

Noncontrolling interests, end of period

 

$

1,555

 

$

1,938

 

$

1,555

 

$

1,938

 

 

In July 2006, the Company, together with two of its wholly-owned subsidiaries, entered into an Amended and Restated Agreement of Limited Liability Company of IMS Health Licensing Associates, L.L.C. (the “Amended LLC Agreement”).  The Amended LLC Agreement governed the relationship between the Company, its subsidiaries and two third-party investors with respect to their interests in IMS Health Licensing Associates, L.L.C. (the “LLC”).  The LLC is a separate and distinct legal entity that is in the business of licensing database assets and computer software.  The Company is the sole managing member of the LLC.  From 1997 until June 30, 2009, the Company

 

25



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

and/or its subsidiaries, or their predecessors, had contributed assets to, and held a controlling interest (approximately 93% at June 30, 2009) in the LLC, and the third-party investors had contributed $100,000 to, and held a noncontrolling interest (approximately 7% at June 30, 2009) in the LLC.  Pursuant to the terms of the Amended LLC Agreement, on May 6, 2009, the third-party investors elected to have their noncontrolling interests in the LLC liquidated or purchased by the Company or its designee.  On June 30, 2009, a wholly-owned subsidiary of the Company purchased the third-party investors’ noncontrolling interests in the LLC at a cost of $100,970, which the Company financed through a combination of cash on-hand and borrowings under its revolving credit facility. Following the purchase of the noncontrolling interests, the Company, together with its wholly-owned subsidiaries, hold 100% of the membership interest in the LLC.  These third-party investor contributions qualified as redeemable noncontrolling interests as their redemption was not solely within the control of the Company.  As such, these redeemable noncontrolling interests were presented in mezzanine equity in the Company’s Condensed Consolidated Statements of Financial Position (Unaudited).  Net income related to these redeemable noncontrolling interests amounted to $1,888 for the nine months ended September 30, 2009 and $1,099 and $3,298, respectively, for the three and nine months ended September 30, 2008 and is included in net income attributable to noncontrolling interests in the Company’s Condensed Consolidated Statements of Income (Unaudited).

 

Note 14.  Comprehensive Income

 

The following table sets forth the components of comprehensive (loss) income, net of income tax expense:

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2009

 

2008

 

2009

 

2008

 

Net (loss) income

 

$

(9,259

)

$

77,313

 

$

188,911

 

$

216,849

 

Other comprehensive (loss) income, net of tax:

 

 

 

 

 

 

 

 

 

Foreign currency translation (losses) gains

 

(19,265

)

(59,725

)

19,586

 

(45,749

)

Amortization of postretirement and postemployment balances

 

4,316

 

(251

)

6,061

 

1,010

 

Total other comprehensive (loss) income, net of tax

 

(14,949

)

(59,976

)

25,647

 

(44,739

)

 

 

 

 

 

 

 

 

 

 

Comprehensive (loss) income

 

(24,208

)

17,337

 

214,558

 

172,110

 

Less comprehensive (loss) income attributable to:

 

 

 

 

 

 

 

 

 

Noncontrolling interests in permanent equity

 

124

 

(45

)

(339

)

494

 

Redeemable noncontrolling interests in mezzanine equity

 

 

1,099

 

1,888

 

3,298

 

Comprehensive (loss) income attributable to IMS Health

 

$

(24,332

)

$

16,283

 

$

213,009

 

$

168,318

 

 

Note 15.  Severance, Impairment and Other Charges

 

In response to accelerating healthcare marketplace dynamics compounded by a sustained economic downturn, during the third quarter of 2009, the Company committed to a streamlining program (the “Plan”) designed to eliminate approximately 850 positions in all areas of the Company’s business and in all regions in which the Company operates; however, the majority of actions are planned for the Company’s Europe, Middle East and Africa (“EMEA”) region. As a result of the Company’s plans to

 

26



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

reduce and consolidate the number of operating units, the Plan further includes charges for certain real estate lease impairments along with related accelerated depreciation.

 

During the third quarter of 2009 the Company recorded $104,301 in Severance, impairment and other charges and $2,024 in accelerated Depreciation and other amortization.

 

The severance benefits were calculated pursuant to the terms of established employee protection plans, in accordance with local statutory minimum requirements or individual employee contracts, as applicable.

 

The actions under the Plan were intended to: 1) streamline the Company’s EMEA region organization, including right-sizing the headquarters function, reducing and consolidating the number of operating units across the region, and improving the productivity of production and development activities; 2) leverage the foundational investments in process improvements the Company has made to reduce costs and improve productivity in its Sales, Finance, Human Resources and Customer Delivery and Development organizations; 3) reduce capacity and align the size of the Sales and Management Consulting teams in areas of reduced client demand; and 4) continue to build and invest in high-value, strategic growth areas, which include extending the Company’s capabilities in specialty and patient-centered insights, in serving payers and governments, and in emerging markets for pharmaceuticals.

 

The Company currently estimates that the total charge under the Plan will be in the range of $110,000 to $112,000 in 2009 for severance, impairment and other charges and accelerated depreciation and amortization. The balance is expected to be recorded in during the fourth quarter of 2009 as the Company exits certain real estate facilities.

 

The cash portion is estimated to be in the range of $106,000 to $108,000 and will be funded from cash generated from operations. Employee termination actions under the Plan are expected to be completed by the end of the third quarter of 2010.

 

 

 

Severance

 

Facility

 

Non-Cash

 

Currency

 

 

 

 

 

Related

 

Exit

 

Compensation

 

Translation

 

 

 

 

 

Reserves

 

Charges

 

Charges

 

Adjustments

 

Total

 

Charge at August 31, 2009

 

$

100,653

 

$

2,610

 

$

1,038

 

$

 

$

104,301

 

2009 utilization

 

(1,097

)

 

(1,038

)

 

(2,135

)

Currency translation adjustments

 

 

 

 

1,240

 

1,240

 

Balance at September 30, 2009

 

$

99,556

 

$

2,610

 

$

 

$

1,240

 

$

103,406

 

 

The Company currently expects that cash outlays will be applied against the $103,406 balance remaining in the 2009 third quarter charge at September 30, 2009 as follows:

 

Year Ended December 31,

 

Outlays

 

2009

 

$

23,308

 

2010

 

76,306

 

2011

 

1,744

 

2012

 

361

 

2013

 

268

 

Thereafter

 

1,419

 

Total

 

$

103,406

 

 

27



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

During the second quarter of 2009, the Company recorded $25,428 in charges as a component of operating income.  Of this amount, $17,210 related to non-cash impairment charges for the write-down of certain capitalized software assets to their net realizable values in the Company’s Americas and EMEA regions.  The write-downs were the result of the regular review of the Company’s capitalized software assets.  The remaining $8,218 was for supplier contract-related charges for which the Company will not realize any future economic benefit.

 

During the fourth quarter of 2008, the Company recorded $9,408 of non-cash impairment charges as a component of operating income related to the write-off of certain capitalized software assets in its EMEA and Asia Pacific regions.  This was the result of the discontinuation of certain IMS products at the end of 2008.

 

During the fourth quarter of 2007, the Company committed to a restructuring plan designed to eliminate approximately 1,070 positions worldwide in production and development, sales, marketing, consulting and services and administration.  The plan also included the write-down of two impaired computer software assets and related contract payments to be incurred with no future economic benefit based on the Company’s decision to abandon certain products in its EMEA region.  As a result, the Company recorded $88,690 of Severance, impairment and other charges as a component of operating income in the fourth quarter of 2007.  The severance benefits were calculated pursuant to the terms of established employee protection plans, in accordance with local statutory minimum requirements or individual employee contracts, as applicable.

 

These charges were designed to strengthen client-facing operations worldwide, increase the Company’s operating efficiencies and streamline its cost structure.  Some of the initiatives included in this plan are designed to better align the Company’s resources to help clients manage for change in a challenging climate.

 

The severance and contract payments portion of the fourth quarter 2007 charge was approximately $75,043 and will all be settled in cash. Termination actions under the plan have been completed.

 

 

 

Severance

 

Contract

 

Asset

 

Currency

 

 

 

 

 

Related

 

Related

 

Write-

 

Translation

 

 

 

 

 

Reserves

 

Reserves

 

Downs

 

Adjustments

 

Total

 

Charge at December 31, 2007

 

$

71,583

 

$

3,460

 

$

13,647

 

$

 

$

88,690

 

2007 utilization

 

 

 

(13,647

)

 

(13,647

)

2008 utilization

 

(48,645

)

(2,150

)

 

 

(50,795

)

2009 utilization

 

(15,859

)

(817

)

 

 

(16,676

)

Currency translation adjustments

 

 

 

 

(1,806

)

(1,806

)

Balance at September 30, 2009

 

$

7,079

 

$

493

 

$

 

$

(1,806

)

$

5,766

 

 

28



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

The Company currently expects that cash outlays will be applied against the $5,766 balance remaining in the 2007 fourth quarter charge at September 30, 2009 as follows:

 

Year Ended December 31,

 

Outlays

 

2009

 

$

4,914

 

2010

 

717

 

2011

 

135

 

Total

 

$

5,766

 

 

Note 16.  Operations by Business Segment

 

Operating segments are defined as components of an enterprise about which financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or decision-making groups, in deciding how to allocate resources to an individual segment and in assessing performance of the segment.  The Company operates a globally consistent business model, offering pharmaceutical business information and related services to its customers in more than 100 countries.  See Note 2.

 

The Company maintains regional geographic management to facilitate local execution of its global strategies.  However, the Company maintains global leaders for the majority of its critical business processes; and the most significant performance evaluations and resource allocations made by the Company’s chief operating decision makers are made on a global basis.  As such, the Company has concluded that it maintains one operating and reportable segment.

 

Geographic Financial Information:

 

The following represents selected geographic information for the regions in which the Company operates for the three and nine months ended September 30, 2009 and 2008.

 

 

 

Americas
(1)

 

EMEA
(2)

 

Asia Pacific
(3)

 

Corporate & Other

 

Total
IMS

 

Three months ended September 30, 2009:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

239,807

 

$

213,925

 

$

87,039

 

$

 

$

540,771

 

Operating Income (Loss) (5)

 

$

68,801

 

$

22,991

 

$

30,017

 

$

(127,353

)

$

(5,544

)

Nine months ended September 30, 2009:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

708,628

 

$

630,487

 

$

251,440

 

$

 

$

1,590,555

 

Operating Income (Loss) (5)

 

$

199,582

 

$

67,638

 

$

88,681

 

$

(191,293

)

$

164,608

 

Three months ended September 30, 2008:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

251,332

 

$

243,219

 

$

79,164

 

$

 

$

573,715

 

Operating Income (Loss) (5)

 

$

75,275

 

$

34,276

 

$

27,266

 

$

(12,841

)

$

123,976

 

Nine months ended September 30, 2008:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

760,783

 

$

744,513

 

$

243,308

 

$

 

$

1,748,604

 

Operating Income (Loss) (5)

 

$

236,866

 

$

83,122

 

$

89,782

 

$

(38,035

)

$

371,735

 

 


Notes to Geographic Financial Information:

 

(1)

 

Americas includes the United States, Canada and Latin America.

 

29



Table of Contents

 

IMS HEALTH INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(Dollars and shares in thousands, except per share data)

 

(2)

 

EMEA includes countries in Europe, the Middle East and Africa.

(3)

 

Asia Pacific includes Japan, Australia and other countries in the Asia Pacific region.

(4)

 

Operating Revenue relates to external customers and is primarily based on the location of the customer. The Operating Revenue for the geographic regions includes the impact of foreign exchange in converting results into U.S. dollars.

(5)

 

Operating Income for the three geographic regions does not reflect the allocation of certain expenses (including severance, impairment and other charges) that are maintained in Corporate and Other and as such, is not a true measure of the respective regions’ profitability. The Operating Income amounts for the geographic segments include the impact of foreign exchange in converting results into U.S. dollars.

 

A summary of the Company’s operating revenue by product line for the three and nine months ended September 30, 2009 and 2008 is presented below:

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2009

 

2008

 

2009

 

2008

 

Commercial Effectiveness

 

$

269,996

 

$

279,816

 

$

793,019

 

$

866,598

 

Product & Portfolio Management

 

168,842

 

174,640

 

502,846

 

544,861

 

New Business Areas

 

101,933

 

119,259

 

294,690

 

337,145

 

Operating Revenue

 

$

540,771

 

$

573,715

 

$

1,590,555

 

$

1,748,604

 

 

Note 17Subsequent Events

 

On October 20, 2009, the Company announced that it is exploring a variety of strategic alternatives. The Company further stated that as part of the process, the Board of Directors has formed a committee, which has retained a financial advisor. The Company has also retained its own financial advisor. There can be no assurance that the exploration of strategic alternatives will result in a transaction.

 

30



Table of Contents

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

(Dollars and shares in thousands, except per share data)

 

This discussion and analysis should be read in conjunction with the accompanying Condensed Consolidated Financial Statements (Unaudited) and related notes.

 

Executive Summary

 

Our Business

 

IMS Health Incorporated (“IMS,” “we,” “us” or “our”) is the leading global provider of market intelligence to the pharmaceutical and healthcare industries. We offer leading-edge market intelligence products and services that are integral to our clients’ day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Our information products are developed to meet client needs by using data secured from a worldwide network of suppliers in more than 100 countries. Our business lines are:

 

·      Commercial Effectiveness to increase clients’ productivity across end-to-end sales, marketing, promotional and performance management processes;

 

·      Product and Portfolio Management to provide clients with insights into market measurement so they can optimize their product portfolio and strategies; and

 

·      New Business Areas that support pharmaceutical client business initiatives in managed markets, consumer health, and pricing and market access, and that also serve payer and government audiences.

 

Within these business lines, we provide consulting and services that use in-house capabilities and methodologies to assist clients in analyzing and evaluating market trends, strategies and tactics, and to help in the development and implementation of customized software applications and data warehouse tools.

 

We operate in more than 100 countries.

 

We manage on a global business model with global leaders for the majority of our critical business processes and accordingly have one reportable segment.

 

We believe that important measures of our financial condition and results of operations include operating revenue, constant dollar revenue growth, operating income, constant dollar operating income growth, operating margin and cash flows.

 

Performance Overview

 

Operating revenue declined 5.7% to $540,771 in the third quarter of 2009 as compared to $573,715 in the third quarter of 2008 and declined 9.0% to $1,590,555 in the nine months ended September 30, 2009 as compared to $1,748,604 in the nine months ended September 30, 2008 as a result of revenue declines in all three of our business lines.  Our operating income declined $129,520 to an operating loss of $5,544 in the third quarter of 2009 as compared to $123,976 of operating income in the third quarter of 2008 due to $104,301 of severance, impairment and other charges and the related $2,024 non-cash charge for accelerated depreciation and amortization, the decrease in our operating revenue and an increase in our selling and administrative expenses, partially offset by decreases in our operating costs, as discussed below.

 

31



Table of Contents

 

Our operating income declined $207,127 to $164,608 in the nine months ended September 30, 2009 as compared to $371,735 in the nine months ended September 30, 2008 due to the decrease in our operating revenue, $129,729 of severance, impairment and other charges and the related $2,024 non-cash charge for accelerated depreciation and amortization, partially offset by decreases in our operating costs and selling and administrative expenses, as discussed below.  Our net income attributable to IMS declined $85,212 to a net loss of $9,300 for the third quarter of 2009 as compared to net income of $75,912 for the third quarter of 2008 due to the decrease in operating income and an increase in the non-operating loss, net items discussed below, partially offset by certain tax items as discussed in Note 11 of the Condensed Consolidated Financial Statements (Unaudited).  Our net income attributable to IMS declined $25,865 to $186,917 for the nine months ended September 30, 2009 as compared to $212,782 for the nine months ended September 30, 2008 due to the decrease in operating income, partially offset by a decrease in the non-operating loss, net items discussed below and certain tax items as discussed in Note 11 of the Condensed Consolidated Financial Statements (Unaudited).  Our diluted earnings per share of Common Stock decreased to a loss of $0.05 for the third quarter of 2009 as compared to income of $0.41 for the third quarter of 2008 and decreased to income of $1.02 for the nine months ended September 30, 2009 as compared to $1.16 for the nine months ended September 30, 2008.

 

Results of Operations

 

Reclassifications. Certain prior-year amounts have been reclassified to conform to the 2009 presentation.

 

References to constant dollar results and results excluding the effect of foreign currency translations.  We report results in U.S. dollars, but we do business on a global basis.  Exchange rate fluctuations affect the rate at which we translate foreign revenues and expenses into U.S. dollars and may have significant effects on our results.  In order to illustrate these effects, the discussion of our business in this report sometimes describes the magnitude of changes in constant dollar terms or results excluding the effect of foreign currency translations.  We believe this information facilitates a comparative view of our business.  In the first nine months of 2009, the U.S. dollar was generally stronger against the other currencies in which we transact business as compared to the first nine months of 2008.  The revenue decline at actual currency rates was greater than the decline at constant dollar exchange rates.  See “How Exchange Rates Affect Our Results” below and the discussion of “Market Risk” in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of our annual report on Form 10-K for the year ended December 31, 2008 for a more complete discussion regarding the impact of foreign currency translation on our business.

 

References to selling and administrative expenses, operating income and operating margin excluding severance, impairment and other charges, the non-cash charge for accelerated depreciation and amortization and the 2008 Government Solutions charge. We discuss below what our selling and administrative expenses, operating income and operating margin for the three and nine months ended September 30, 2009 and 2008 would have been had we not recorded severance, impairment and other charges, the non-cash charge for accelerated depreciation and amortization and the 2008 Government Solutions charge. Because we did not record similar charges in the prior periods, we believe providing these non-GAAP measures is useful to investors as it facilitates comparisons across the periods presented and more clearly indicates trends. Management uses these non-GAAP measures in its global decision-making, including developing budgets and managing expenditures.

 

32



Table of Contents

 

Summary of Operating Results

 

 

 

 

 

 

 

% Variance

 

 

 

Three Months Ended September 30,

 

2009

 

 

 

2009

 

2008

 

vs 2008

 

Information and analytics revenue (I&A)

 

$

425,197

 

$

445,654

 

(4.6

)%

Consulting and services revenue (C&S)

 

115,574

 

128,061

 

(9.8

)%

Operating Revenue

 

540,771

 

573,715

 

(5.7

)%

 

 

 

 

 

 

 

 

Operating costs of I&A

 

181,974

 

190,139

 

4.3

%

Direct and incremental costs of C&S

 

58,774

 

62,185

 

5.5

%

External-use software amortization

 

9,823

 

12,291

 

20.1

%

Selling and administrative expenses

 

166,885

 

161,878

 

(3.1

)%

Depreciation and other amortization

 

24,558

 

23,246

 

(5.6

)%

Severance, impairment and other charges

 

104,301

 

 

 

Operating Income

 

$

(5,544

)

$

123,976

 

(104.5

)%

 

 

 

 

 

 

 

% Variance

 

 

 

Nine Months Ended September 30,

 

2009

 

 

 

2009

 

2008

 

vs 2008

 

Information and analytics revenue (I&A)

 

$

1,253,885

 

$

1,355,281

 

(7.5

)%

Consulting and services revenue (C&S)

 

336,670

 

393,323

 

(14.4

)%

Operating Revenue

 

1,590,555

 

1,748,604

 

(9.0

)%

 

 

 

 

 

 

 

 

Operating costs of I&A

 

528,213

 

576,514

 

8.4

%

Direct and incremental costs of C&S

 

176,931

 

202,641

 

12.7

%

External-use software amortization

 

30,464

 

38,048

 

19.9

%

Selling and administrative expenses

 

490,211

 

493,010

 

0.6

%

Depreciation and other amortization

 

70,399

 

66,656

 

(5.6

)%

Severance, impairment and other charges

 

129,729

 

 

 

Operating Income

 

$

164,608

 

$

371,735

 

(55.7

)%

 

Operating Income

 

Our operating income for the third quarter of 2009 declined $129,520 to an operating loss of $5,544 from $123,976 of operating income in the third quarter of 2008.  This was due to $104,301 of severance, impairment and other charges and the related $2,024 non-cash charge for accelerated depreciation and amortization (see Note 15 to our Condensed Consolidated Financial Statements (Unaudited)), the decrease in our operating revenue and an increase in our selling and administrative expenses, partially offset by decreases in our operating costs driven by decreased cost of data and tight controls on hiring.  Our operating income decreased $133,643 or 115.3% in constant dollar terms. Absent the impact of severance, impairment and other charges and the related non-cash charge for accelerated depreciation and amortization and the 2008 Government Solutions charge of $3,748 (see Note 7 to our Condensed Consolidated Financial Statements (Unaudited)), non-GAAP operating income would have decreased 21.1% at reported rates and 27.8% in constant dollar terms (see “Reconciliation of U.S. GAAP Measures to Non-GAAP Measures” at the end of this Item 2).  Our operating income for the first nine months of 2009 declined $207,127 to $164,608 from $371,735 in the first nine months of 2008.  This was due to the decrease in our operating

 

33



Table of Contents

 

revenue, $129,729 of severance, impairment and other charges and the related $2,024 non-cash charge for accelerated depreciation and amortization, partially offset by decreases in our operating costs and selling and administrative expenses driven by decreased cost of data and tight controls on hiring.  Our operating income decreased $218,021 or 63.7% in constant dollar terms.  Absent the impact of severance, impairment and other charges and the related non-cash charge for accelerated depreciation and amortization and the 2008 Government Solutions charge of $3,748, non-GAAP operating income would have decreased 21.1% at reported rates and 27.0% in constant dollar terms (see “Reconciliation of U.S. GAAP Measures to Non-GAAP Measures” at the end of this Item 2).

 

Operating Revenue

 

Our operating revenue for the third quarter of 2009 declined 5.7% to $540,771 from $573,715 in the third quarter of 2008. On a constant dollar basis, operating revenue declined 4.1%.  Operating revenue for the first nine months of 2009 declined 9.0% to $1,590,555 from $1,748,604 in the first nine months of 2008. On a constant dollar basis, operating revenue declined 4.7%.  On a constant dollar basis, acquisitions completed within the prior twelve months contributed approximately 0.4 percentage points and 0.6 percentage points of revenue growth for the third quarter and first nine months of 2009, respectively, partially offsetting our operating revenue decline for these same periods.  The decrease in our operating revenue resulted from revenue declines in all three of our business lines, together with the effect of approximately $11,000 and $82,000 of currency translation for the third quarter and first nine months of 2009, respectively, as compared to the third quarter and first nine months of 2008.

 

Summary of Operating Revenue

 

 

 

 

 

 

 

% Variance

 

 

 

 

 

2009 vs 2008

 

 

 

Three Months Ended September 30,

 

Reported

 

Constant

 

 

 

2009

 

2008

 

Rates

 

Dollar

 

Commercial Effectiveness

 

$

269,996

 

$

279,816

 

(3.5

)%

(2.6

)%

Product & Portfolio Management

 

168,842

 

174,640

 

(3.3

)%

(1.6

)%

New Business Areas

 

101,933

 

119,259

 

(14.5

)%

(11.2

)%

Operating Revenue

 

$

540,771

 

$

573,715

 

(5.7

)%

(4.1

)%

 

 

 

 

 

 

 

% Variance

 

 

 

 

 

2009 vs 2008

 

 

 

Nine Months Ended September 30,

 

Reported

 

Constant

 

 

 

2009

 

2008

 

Rates

 

Dollar

 

Commercial Effectiveness

 

$

793,019

 

$

866,598

 

(8.5

)%

(4.7

)%

Product & Portfolio Management

 

502,846

 

544,861

 

(7.7

)%

(3.2

)%

New Business Areas

 

294,690

 

337,145

 

(12.6

)%

(6.9

)%

Operating Revenue

 

$

1,590,555

 

$

1,748,604

 

(9.0

)%

(4.7

)%

 

·      Commercial Effectiveness: EMEA contributed approximately two-thirds and the Americas contributed more than one-third to the constant dollar revenue decline for the third quarter of 2009, slightly offset by revenue growth in Asia Pacific.  Each of EMEA and the Americas contributed approximately one-half to the constant dollar revenue decline for the first nine months of 2009,

 

34



Table of Contents

 

slightly offset by revenue growth in Asia Pacific.

 

·      Product & Portfolio Management: The Americas contributed more than two-thirds and EMEA contributed more than one-quarter to the constant dollar revenue decline for the third quarter of 2009, slightly offset by revenue growth in Asia Pacific.  Each of EMEA and the Americas contributed approximately one-half to the constant dollar revenue decline for the first nine months of 2009.

 

·      New Business Areas: EMEA contributed approximately three-quarters and the Americas contributed approximately one-quarter to the constant dollar revenue decline for the third quarter of 2009, slightly offset by revenue growth in Asia Pacific.  Each of EMEA and the Americas contributed approximately one-half to the constant dollar revenue decline for the first nine months of 2009.

 

Consulting and services (“C&S”) revenue, as included in the business lines above, was $115,574 in the third quarter of 2009, down 9.8% from $128,061 in the third quarter of 2008 (down 7.5% on a constant dollar basis). C&S revenue was $336,670 in the first nine months of 2009, down 14.4% from $393,323 in the first nine months of 2008 (down 9.8% on a constant dollar basis).

 

Operating Costs of Information and Analytics

 

Operating costs of information and analytics (“I&A”) include costs of data, data processing and collection and costs attributable to personnel involved in production, data management and delivery of our I&A offerings.

 

Our operating costs of I&A declined 4.3% to $181,974 in the third quarter of 2009 from $190,139 in the third quarter of 2008 and declined 8.4% to $528,213 in the first nine months of 2009 from $576,514 in the first nine months of 2008.

 

·      Foreign Currency Translation: The effect of foreign currency translation decreased our operating costs of I&A by approximately $6,000 and $36,000 for the third quarter and first nine months of 2009, respectively, as compared to the third quarter and first nine months of 2008.

 

Excluding the effect of foreign currency translation, our operating costs of I&A declined 1.2% and 2.3% in the third quarter and first nine months of 2009, respectively, as compared to the third quarter and first nine months of 2008.

 

·      Data: Data costs decreased by approximately $2,000 and $12,000 in the third quarter and first nine months of 2009, respectively, as compared to the third quarter and first nine months of 2008.

 

Direct and Incremental Costs of Consulting and Services

 

Direct and incremental costs of C&S include the costs of consulting staff directly involved with delivering revenue-generating engagements, related accommodations and the costs of primary market research data purchased specifically for certain individual C&S engagements.  Direct and incremental costs of C&S do not include an allocation of direct costs of data that are included within I&A.

 

Our direct and incremental costs of C&S declined 5.5% to $58,774 in the third quarter of 2009 from $62,185 in the third quarter of 2008 and declined 12.7% to $176,931 in the first nine months of 2009 from

 

35



Table of Contents

 

$202,641 in the first nine months of 2008.

 

·      Foreign Currency Translation: The effect of foreign currency translation decreased our direct and incremental costs of C&S by approximately $4,000 and $16,000 for the third quarter and first nine months of 2009, respectively, as compared to the third quarter and first nine months of 2008.

 

Excluding the effect of foreign currency translation, our direct and incremental costs of C&S increased 0.5% in the third quarter of 2009 as compared to the third quarter of 2008 and declined 5.2% in the first nine months of 2009 as compared to the first nine months of 2008.

 

C&S costs in the third quarter of 2009 were comparable to the third quarter of 2008.  C&S costs decreased by approximately $10,000 in the first nine months of 2009 as compared to the first nine months of 2008, due to decreased labor cost.

 

External-Use Software Amortization

 

Our external-use software amortization charges represent the amortization associated with capitalized software to be sold, leased, or otherwise marketed.  Our external-use software amortization charges declined 20.1% to $9,823 in the third quarter of 2009 from $12,291 in the third quarter of 2008 and declined 19.9% to $30,464 in the first nine months of 2009 from $38,048 in the first nine months of 2008. This was due to decreased software amortization associated with assets that were fully amortized or written-down to their net realizable values.

 

Selling and Administrative Expenses

 

Our selling and administrative expenses consist primarily of the expenses attributable to sales, marketing, and administration, including human resources, legal, management and finance.  Our selling and administrative expenses increased 3.1% to $166,885 in the third quarter of 2009 from $161,878 in the third quarter of 2008 and declined 0.6% to $490,211 in the first nine months of 2009 from $493,010 in the first nine months of 2008.  Absent the 2008 Government Solutions charge of $3,748 (see Note 7 to our Condensed Consolidated Financial Statements (Unaudited)), our non-GAAP selling and administrative expenses would have grown 5.5% and 0.2% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008 (see “Reconciliation of U.S. GAAP Measures to Non-GAAP Measures” at the end of this Item 2).

 

·      Foreign Currency Translation: The effect of foreign currency translation decreased our selling and administrative expenses by approximately $7,000 and $41,000 for the third quarter and first nine months of 2009, respectively, as compared to the third quarter and first nine months of 2008.

 

Excluding the effect of foreign currency translation and the Government Solutions charge, our non-GAAP selling and administrative expenses grew 10.4% and 9.1% in third quarter and first nine months of 2009, respectively, as compared to the third quarter and first nine months of 2008.

 

·      Sales and Marketing: Sales and marketing expenses decreased $2,000 and $4,000 in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008.

 

·      Consulting and Services:  C&S expenses remained relatively flat in the third quarter of 2009 as compared to the third quarter of 2008.  C&S expenses increased $16,000 in the first nine months of

 

36



Table of Contents

 

2009 as compared to the first nine months of 2008.  Absent the 2008 Government Solutions charge, C&S expenses would have increased by approximately $4,000 in the third quarter of 2009 as compared to the third quarter of 2008 and increased by approximately $20,000 in the first nine months of 2009 as compared to the first nine months of 2008.

 

·      Administrative and Other:  Other expenses increased $13,000 in the third quarter of 2009 as compared to the third quarter of 2008 and increased $26,000 in the first nine months of 2009 as compared to the first nine months of 2008.

 

Depreciation and Other Amortization

 

Our depreciation and other amortization charges increased 5.6% to $24,558 in the third quarter of 2009 from $23,246 in the third quarter of 2008, and 5.6% to $70,399 in the first nine months of 2009 from $66,656 in the first nine months of 2008, due to $2,024 of accelerated depreciation and amortization recorded in the three months ended September 30, 2009 primarily related to exited facilities as part of the streamlining program noted under Severance, impairment and other charges below.

 

Severance, impairment and other charges

 

During the third quarter of 2009, we recorded $104,301 in charges as a component of operating income for employee termination benefits and facility exit costs as a result of the streamlining program announced by the Company in July 2009 in response to accelerating healthcare marketplace dynamics compounded by a sustained economic downturn. During the second quarter of 2009, we recorded $25,428 in charges as a component of operating income related to non-cash impairment charges for the write-down of certain capitalized software assets to their net realizable values in our Americas and EMEA regions and for supplier contract-related charges for which we will not realize any future economic benefit. See Note 15 to our Condensed Consolidated Financial Statements (Unaudited).

 

Trends in our Operations

 

Our operating margin for the third quarter of 2009 was (1.0)% as compared to 21.6% in the third quarter of 2008.  Our operating margin for the first nine months of 2009 was 10.3% as compared to 21.3% in the first nine months of 2008. Margins were negatively impacted by revenue declines and the severance, impairment and other charges and related accelerated depreciation and amortization noted above, partially offset by decreased costs of panel and decreased sales and marketing costs. Excluding the severance, impairment and other charges and related accelerated depreciation and amortization noted above, our non-GAAP operating margin for both the three and nine months ended September 30, 2009 would have been 18.6% (see “Reconciliation of U.S. GAAP Measures to Non-GAAP Measures” at the end of this Item 2).

 

We have several offerings in the U.S. that utilize prescriber-identifiable information.  Over the past several years, there have been a number of state legislative initiatives seeking to impose restrictions on the commercial use of such information. To date, three states, New Hampshire, Vermont and Maine, have passed laws placing certain restrictions on the license, use or transfer of prescriber-identifiable information for commercial purposes. Collectively, these three states represent approximately one percent of prescription activity in the U.S. and therefore the impact of these laws on our business, financial condition and results of operations is not expected to be material. For additional information regarding the status of the laws passed in the three states noted above and related legislative developments in other jurisdictions, see Part II. Item 1A. Risk Factors.

 

37



Table of Contents

 

Non-Operating Loss, Net

 

Our non-operating loss, net, increased to $17,189 in the third quarter of 2009 from $11,614 in the third quarter of 2008 and decreased to $24,818 in the first nine months of 2009 from $54,053 in the first nine months of 2008.  This was due to the following factors:

 

·      Interest Expense, net: Net interest expense was $8,778 and $25,825 for the third quarter and first nine months of 2009, respectively, as compared to $9,012 and $26,670 for the third quarter and first nine months of 2008.  This improvement was due to lower debt levels and lower borrowing costs in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008.

 

·      Gains (Losses) from Investments, net:  In the third quarter of 2009, we incurred a loss of $618 related to the write down for other-than-temporary declines in the value of certain investments.  In the third quarter of 2008, gains from investments of $379 were the result of the sale of marketable securities.

 

·      Other Income (Expense), net: Other income, net, declined by $4,812 in the third quarter of 2009 as compared to the third quarter of 2008.  This was a result of net foreign exchange losses of $7,694 in the third quarter of 2009 as compared to net foreign exchange losses of $2,934 in the third quarter of 2008. Other income, net, grew by $29,350 in the first nine months of 2009 as compared to the first nine months of 2008.  This was a result of net foreign exchange gains of $1,727 in the first nine months of 2009 as compared to net foreign exchange losses of $27,662 in the first nine months of 2008.

 

Taxes

 

We operate in more than 100 countries around the world and our earnings are taxed at the applicable income tax rate in each of these countries.

 

For the three months ended September 30, 2009, our effective tax rate was reduced by the expiration of certain statutes of limitation (tax benefits of $14,100).  For the nine months ended September 30, 2009, our effective tax rate was reduced as a result of the expiration of certain statutes of limitation (tax benefits of $14,100), the reorganization of certain subsidiaries which resulted in a foreign exchange loss recognized for tax purposes (tax benefit of $63,200), the settlement of a certain state tax matter (tax benefit of $16,300), the resolution of certain legacy tax matters (tax benefit of $9,500) (see Note 7 to our Condensed Consolidated Financial Statements (Unaudited),“Sharing Disputes.”) and the repayment of a certain intercompany loan which resulted in a foreign exchange loss recognized for tax purposes (tax benefit of $6,100).  For the three months ended September 30, 2008, our effective rate was reduced by the resolution of a certain legacy tax matter (tax benefit of $5,900).  For the nine months ended September 30, 2008, our effective tax rate was reduced by the resolution of a certain legacy tax matter (tax benefit of $5,900), by the result of audit settlements with taxing authorities (tax benefit of $10,300), and the result of filing an advance pricing agreement (“APA”) between two taxing jurisdictions (tax benefit of $4,900).  The APA ensures conformity between the jurisdictions’ taxing authorities regarding the treatment of certain intercompany transactions, thereby allowing us to record a corresponding tax benefit.  Also during this period, we recorded tax expense for tax positions related to non-US transactions offset by a benefit related to the expiration of certain statutes of limitation (net tax expense of $4,300).

 

38



Table of Contents

 

For the three and nine months ended September 30, 2009, we recorded $5,300 and $12,500, respectively, of tax expense related to unrecognized tax benefits that if recognized, would favorably affect the effective tax rate.  Interest and penalties of $800 and $3,300, respectively, are included in these amounts. For the three and nine months ended September 30, 2008, we recorded $5,200 and $15,200, respectively, of tax expense related to unrecognized tax benefits including $2,500 and $7,800, respectively, of interest and penalties.

 

We file numerous consolidated and separate income tax returns in U.S. (federal and state) and non-U.S. jurisdictions.  We are no longer subject to U.S. federal income tax examination by tax authorities for years before 2006. We are no longer subject to state and local income tax examination by tax authorities for years before 1997. Further, with few exceptions, we are no longer subject to examination by tax authorities in its material non-U.S. jurisdictions prior to 2004.  It is reasonably possible that within the next twelve months we could realize $26,700 of unrecognized tax benefits as a result of the expiration of certain statutes of limitation.

 

While we intend to continue to seek global tax planning initiatives, there can be no assurance that we will be able to successfully identify and implement such initiatives to reduce or maintain our overall tax rate and therefore rates may go up in the future.

 

Net Income Attributable to Noncontrolling Interests

 

On January 1, 2009, we adopted authoritative guidance which established accounting and reporting standards pertaining to ownership interests in subsidiaries held by parties other than the parent, the amount of net income attributable to the parent and to the noncontrolling interests, changes in a parent’s ownership interests, and the valuation of any retained noncontrolling equity investment when a subsidiary is deconsolidated.  As a result of the adoption of this authoritative guidance, net income attributable to noncontrolling interests, which previously was included in Other expense, net on a pretax basis, is shown separately from net income attributable to us in our Condensed Consolidated Statements of Income (Unaudited).  Net Income Attributable to Noncontrolling Interests decreased to $41 and $1,994 in the third quarter and first nine months of 2009, respectively, from $1,401 and $4,067 in the third quarter and first nine months of 2008, respectively, due to the liquidation of third-party investors’ noncontrolling interests in IMS Health Licensing Associates, L.L.C. in second quarter of 2009. See Note 13 to our Condensed Consolidated Financial Statements (Unaudited).

 

39



Table of Contents

 

Operating Results by Geographic Region

 

The following represents selected geographic information for the regions in which we operate for the three and nine months ended September 30, 2009 and 2008:

 

 

 

Americas
(1)

 

EMEA
(2)

 

Asia Pacific
(3)

 

Corporate & Other

 

Total
IMS

 

Three months ended September 30, 2009:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

239,807

 

$

213,925

 

$

87,039

 

$

 

$

540,771

 

Operating Income (Loss) (5)

 

$

68,801

 

$

22,991

 

$

30,017

 

$

(127,353

)

$

(5,544

)

Nine months ended September 30, 2009:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

708,628

 

$

630,487

 

$

251,440

 

$

 

$

1,590,555

 

Operating Income (Loss) (5)

 

$

199,582

 

$

67,638

 

$

88,681

 

$

(191,293

)

$

164,608

 

Three months ended September 30, 2008:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

251,332

 

$

243,219

 

$

79,164

 

$

 

$

573,715

 

Operating Income (Loss) (5)

 

$

75,275

 

$

34,276

 

$

27,266

 

$

(12,841

)

$

123,976

 

Nine months ended September 30, 2008:

 

 

 

 

 

 

 

 

 

 

 

Operating Revenue (4)

 

$

760,783

 

$

744,513

 

$

243,308

 

$

 

$

1,748,604

 

Operating Income (Loss) (5)

 

$

236,866

 

$

83,122

 

$

89,782

 

$

(38,035

)

$

371,735

 

 


Notes to Geographic Financial Information:

 

(1)

 

Americas includes the United States, Canada and Latin America.

(2)

 

EMEA includes countries in Europe, the Middle East and Africa.

(3)

 

Asia Pacific includes Japan, Australia and other countries in the Asia Pacific region.

(4)

 

Operating Revenue relates to external customers and is primarily based on the location of the customer. The Operating Revenue for the geographic regions includes the impact of foreign exchange in converting results into U.S. dollars.

(5)

 

Operating Income for the three geographic regions does not reflect the allocation of certain expenses (including severance, impairment and other charges) that are maintained in Corporate and Other and as such, is not a true measure of the respective regions’ profitability. The Operating Income amounts for the geographic segments include the impact of foreign exchange in converting results into U.S. dollars.

 

 

Americas Region

 

Operating revenue declined 4.6% and 6.9% in the Americas region in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.  Excluding the effect of foreign currency translations, operating revenue declined 3.4% and 4.9% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.  This was driven approximately one-third by Commercial Effectiveness and more than one-third by New Business Areas for the third quarter of 2009.  The revenue decline in the first nine months of 2009 was driven approximately one-half by Commercial Effectiveness and more than one-quarter by New Business Areas.

 

Operating income in the Americas region declined 8.6% and 15.7% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.  The operating income decline reflected revenue declines in the region partially offset by decreases in operating expenses of $5,000 and $15,000 in the third quarter and first nine months of 2009, respectively.  Excluding the effect of foreign currency translations, operating income decreased 7.6% and 14.2% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.

 

40



Table of Contents

 

EMEA Region

 

Operating revenue decreased in the EMEA region by 12.0% and 15.3% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.  Excluding the effect of foreign currency translations, operating revenue declined 7.3% and 6.2% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.  The revenue decline in the third quarter of 2009 was driven approximately one-third by Commercial Effectiveness and approximately two-thirds by New Business Areas. The revenue decline in the first nine months of 2009 was driven more than one-half by Commercial Effectiveness and more than one-quarter by New Business Areas.

 

Operating income in the EMEA region declined 32.9% and 18.6% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.  The operating income decline reflected revenue declines in the region partially offset by decreases in operating expenses of $18,000 and $99,000 in the third quarter and first nine months of 2009, respectively.  Excluding the effect of foreign currency translations, operating income decreased 52.4% and 43.0% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.

 

Asia Pacific Region

 

Operating revenue in the Asia Pacific region increased 9.9% and 3.3% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008.  Excluding the effect of foreign currency translations, operating revenue increased 3.3% and 0.6% in the third quarter and first nine months of 2009 as compared to the third quarter and first nine months of 2008, respectively.  The revenue growth in the third quarter of 2009 was driven about equally by all three of our business lines.  The revenue growth in the first nine months of 2009 was driven approximately two-thirds by Commercial Effectiveness and more than one-third by New Business Areas, partially offset by revenue decline in the Product & Portfolio Management business line.

 

Operating income in the Asia Pacific region grew by 10.1% in the third quarter of 2009 as compared to the third quarter of 2008 and declined 1.2% in the first nine months of 2009 as compared to the first nine months of 2008.  Operating income grew in the third quarter of 2009 as a result of revenue growth in the region partially offset by increases in operating expenses of $5,000.  In the first nine months of 2009, the operating income decline reflected revenue growth in the region more than offset by increases in operating expenses of $9,000.  Excluding the effect of foreign currency translations, operating income grew 1.1% in the third quarter of 2009 as compared to the third quarter of 2008 and decreased by 5.5% in the first nine months of 2009 as compared to the first nine months of 2008.

 

How Exchange Rates Affect Our Results

 

We operate globally, deriving a significant portion of our operating income from non-U.S. operations.  As a result, fluctuations in the value of foreign currencies in which we transact business relative to the U.S. dollar may increase the volatility of U.S. dollar operating results.  We enter into foreign currency forward contracts to partially offset the effect of currency fluctuations. Foreign currency translation increased the U.S. dollar revenue decline by approximately 1.6 and 4.3 percentage points in the third quarter and first nine months of 2009, respectively, while the impact on the operating income decline was an approximate decrease of 10.8 and 8.0 percentage points in the third quarter and first nine months of 2009, respectively. In 2008, foreign currency translation increased U.S. dollar revenue growth by

 

41



Table of Contents

 

approximately 3.9 and 6.0 percentage points in the third quarter and first nine months of 2008, respectively, while the impact on operating income growth was an approximate increase of 4.8 and 7.4 percentage points in the third quarter and first nine months of 2008, respectively.

 

Non-U.S. monetary assets are maintained in currencies other than the U.S. dollar, principally the Euro, the Japanese Yen and the Swiss Franc.  Where monetary assets are held in the functional currency of the local entity, changes in the value of these currencies relative to the U.S. dollar are reflected in Cumulative translation adjustment in the Condensed Consolidated Statements of Financial Position (Unaudited).  The effect of exchange rate changes during the first nine months of 2009 increased the U.S. dollar amount of Cash and cash equivalents by $10,438. The effect of exchange rate changes during the first nine months of 2008 decreased the US dollar amount of cash and cash equivalents by $3,162.

 

Liquidity and Capital Resources

 

Our cash and cash equivalents increased $86,029 to $301,711 at September 30, 2009 compared to $215,682 at December 31, 2008.  The increase reflects cash provided by operating activities of $347,534 and an increase of $10,438 due to the effect of exchange rate changes, partially offset by cash used in investing and financing activities of $79,653 and $192,290, respectively.

 

We currently expect that we will use our Cash and cash equivalents primarily to fund:

 

·   development of software to be used in our new products and capital expenditures to expand and upgrade our information technology capabilities and to build or acquire facilities to house our business (we currently expect to spend approximately $110,000 to $120,000 over the next twelve months for software development and capital expenditures);

 

·   acquisitions (see Note 5 to our Condensed Consolidated Financial Statements (Unaudited));

 

·   dividends to our shareholders (we expect that dividends will be $0.12 per share or approximately $22,000 over the next twelve months);

 

·   payments of approximately $116,000 related to our restructuring plans and our second quarter 2009 supplier contract-related charge, of which approximately $110,000 is expected to be paid over the next twelve months (see Note 15 to our Condensed Consolidated Financial Statements (Unaudited));

 

·   pension and other postretirement benefit plan contributions (we currently expect contributions to U.S. and non-U.S. pension and other postretirement benefit plans to total approximately $10,600 in 2009) (see Note 10 to our Condensed Consolidated Financial Statements (Unaudited) for information regarding our pension and postretirement benefit plan expense); and

 

·   share repurchases (see Note 12 to our Condensed Consolidated Financial Statements (Unaudited)).

 

Net cash provided by operating activities amounted to $347,534 for the nine months ended September 30, 2009, which represented an increase of $94,972 compared to cash provided by operating activities during the comparable period in 2008. The increase relates to higher accrued severance, impairment and other balances (See Note 15 to our Condensed Consolidated Financial Statements (Unaudited)), lower accounts receivable balances, the lower funding of prepaid expenses and other

 

42



Table of Contents

 

current assets, higher deferred revenue balances and the lower funding of accrued expenses and other current liabilities, partially offset by lower accrued taxes and lower net income during the nine months ended September 30, 2009.  The decrease in accounts receivable was driven by a decrease in DSO (days sales outstanding), which was ten days lower in the third quarter of 2009 as compared to the prior year comparable quarter. The decrease in DSO was the result of improved collections and receivables management and lower revenue.

 

Net cash used in investing activities amounted to $79,653 for the nine months ended September 30, 2009, a decrease in cash used of $56,554 over the comparable period in 2008.  The decrease relates to lower payments for acquisitions and lower capital expenditures, partially offset by higher additions to computer software during the nine months ended September 30, 2009 as compared to the prior year comparable period.

 

Net cash used in financing activities amounted to $192,290 for the nine months ended September 30, 2009, an increase of $90,036 compared to cash used in financing activities during the comparable period in 2008.  This increase was due to lower net borrowings of debt, the purchase of third-party ownership interests in IMS Health Licensing Associates, L.L.C. (see Note 13 to our Condensed Consolidated Financial Statements (Unaudited)), lower proceeds from the exercise of stock options and a decrease in cash overdrafts, partially offset by lower purchases of treasury stock during the nine months ended September 30, 2009 as compared to the prior year comparable period.

 

Our financing activities include cash dividends we paid of $0.03 per share quarterly, which amounted to $16,151 and $16,626 during the nine months ended September 30, 2009 and 2008, respectively.  The payments and level of cash dividends made by us are subject to the discretion of our Board of Directors.  Any future dividends, other than the $0.03 per share dividend for the fourth quarter of 2009, which was declared by our Board of Directors in October 2009, will be based on, and affected by, a number of factors, including our operating results and financial requirements.

 

Capital and Credit Markets

 

As the capital and credit markets have contracted, we have performed additional assessments to determine the impact, if any, on our financial statements of recent market developments, including the restructuring or merging of certain financial institutions. Our additional assessments included a review of access to liquidity in the capital and credit markets and financial institution counterparty creditworthiness.  Based on our assessment, we currently believe we have sufficient liquidity and access to credit despite the current condition of the capital and credit markets.

 

Liquidity in the Capital and Credit Markets

 

We fund our liquidity needs for capital investment, working capital, and other financial commitments through cash flow from continuing operations and our diversified credit facility ($480,314 in aggregate commitment available as of September 30, 2009). While not significant to us to date, contraction in capital and credit markets may result in increased borrowing costs in the future.

 

43



Table of Contents

 

Credit Concentrations

 

We continually monitor our positions with, and the credit quality of, the financial institutions which are counterparties to our financial instruments and do not anticipate non-performance by the counterparties.  We would not have realized a material loss during the quarter ended September 30, 2009 in the event of non-performance by any one counterparty.  In general, we enter into transactions only with financial institution counterparties that have a credit rating of A or better.  In addition, we limit the amount of credit exposure with any one institution.  Particularly in light of the current credit environment, management will continue to monitor the status of these counterparties and will take action, as appropriate, to further manage its counterparty credit risk.

 

We maintain accounts receivable balances ($309,136 and $382,776, net of allowances, at September 30, 2009 and December 31, 2008, respectively), principally from customers in the pharmaceutical industry.  Our trade receivables do not represent significant concentrations of credit risk at September 30, 2009 due to the credit worthiness of our customers and their dispersion across many geographic areas.

 

Tax and Other Contingencies

 

We are exposed to certain known tax and other contingencies that are material to our investors.  The facts and circumstances surrounding these contingencies and a discussion of their effect on us are included in Notes 7 and 11 to our Condensed Consolidated Financial Statements (Unaudited) for the period ended September 30, 2009.

 

These contingencies may have a material effect on our liquidity, capital resources or results of operations. In addition, even where our reserves are adequate, the incurrence of any of these liabilities may have a material effect on our liquidity and the amount of cash available to us for other purposes.

 

Management believes that we have made appropriate arrangements in respect of the future effect on us of these known tax and other contingencies.  Management also believes that the amount of cash available to us from our operations, together with cash from financing, will be sufficient for us to pay any known tax and other contingencies as they become due without materially affecting our ability to conduct our operations and invest in the growth of our business.

 

Stock Repurchase Programs

 

Our share repurchase program has been developed to buy opportunistically, when we believe that our share price provides us with an attractive use of our cash flow and debt capacity.

 

On December 18, 2007, the Board of Directors authorized a stock repurchase program to buy up to 20,000 shares. As of September 30, 2009, 9,505 shares remained available for repurchase under the December 2007 program.

 

During the nine months ended September 30, 2009, we did not repurchase any shares of outstanding Common Stock under this program.

 

During the nine months ended September 30, 2008, we repurchased 10,055 shares of outstanding Common Stock under this program at a total cost of $230,433.

 

44



Table of Contents

 

These share repurchases positively impacted our diluted earnings per share by $0.01 and $0.03 for the three and nine months ended September 30, 2008, respectively.

 

Shares acquired through our repurchase programs described above are open-market purchases or privately negotiated transactions in compliance with SEC Rule 10b-18.

 

Under our Restated Certificate of Incorporation as amended, we have the authority to issue 820,000 shares with a par value of $.01 per share of which 800,000 represent shares of Common Stock, 10,000 represent shares of preferred stock and 10,000 represent shares of Series Common Stock.  The preferred stock and Series Common Stock can be issued with varying terms, as determined by the Board of Directors.

 

Borrowings

 

In recent years, we have increased debt levels to balance appropriately the objective of generating an attractive cost of capital with providing us a reasonable amount of financial flexibility.  At September 30, 2009, our debt totaled $1,344,850, and management does not believe that this level of debt poses a material risk to us due to the following factors:

 

·      in each of the last three years, we have generated strong net cash provided by operating activities in excess of $350,000;

 

·      at September 30, 2009, we had $301,711 in worldwide cash and cash equivalents;

 

·      at September 30, 2009, we had $480,314 of unused debt capacity under our existing bank credit facilities; and

 

·      we believe that we have the ability to obtain additional debt capacity outside of our existing debt arrangements.

 

The following table summarizes our long-term debt at September 30, 2009 and December 31, 2008:

 

 

 

2009

 

2008

 

5.58% Private Placement Notes, principal payment of $105,000 due January 2015

 

$

105,000

 

$

105,000

 

5.99% Private Placement Notes, principal payment of $135,000 due January 2018

 

135,000

 

135,000

 

5.55% Private Placement Notes, principal payment of $150,000 due April 2016

 

150,000

 

150,000

 

1.70% Private Placement Note, principal payment of 34,395,000 Japanese Yen due January 2013

 

385,164

 

381,304

 

Revolving Credit Facility:

 

 

 

 

 

Japanese Yen denominated borrowings at average floating rates of approximately 0.78%

 

360,686

 

435,895

 

U.S. Dollar denominated borrowings at average floating rates of approximately 0.65%

 

159,000

 

147,000

 

Bank Term Loan, principal payment of $50,000 due June 2011 at average floating rate of approximately 0.59%

 

50,000

 

50,000

 

Total Long-Term Debt

 

$

1,344,850

 

$

1,404,199

 

 

In February 2008, we closed a private placement transaction pursuant to which we issued $105,000 of seven-year debt at a fixed rate of 5.58%, and $135,000 of ten-year debt at a fixed rate of 5.99% to several

 

45



Table of Contents

 

highly rated insurance companies. We used the proceeds for share repurchases (see Note 12 to our Condensed Consolidated Financial Statements (Unaudited)) and to refinance existing debt.

 

In July 2006, we entered into a $1,000,000 revolving credit facility with a syndicate of 12 banks (“Revolving Credit Facility”) replacing our existing $700,000 facility.  The terms of the Revolving Credit Facility extended the maturity of the facility in its entirety to a term of five years, maturing July 2011, reduced the borrowing margins, and increased subsidiary borrowing limits.  Total borrowings under the Revolving Credit Facility were $519,686 and $582,895 at September 30, 2009 and December 31, 2008, respectively, all of which were classified as long-term.  We define long-term lines as those where the lines are non-cancellable for more than 365 days from the balance sheet date by the financial institutions except for specified, objectively measurable violations of the provisions of the agreement.  In general, rates for borrowing under the Revolving Credit Facility are LIBOR plus 40 basis points and can vary based on our Debt to EBITDA ratio. The weighted average interest rates for our lines were 0.74% and 1.36% at September 30, 2009 and December 31, 2008, respectively.  In addition, we are required to pay a commitment fee on any unused portion of the facilities of 0.01%. At September 30, 2009, we had approximately $480,314 available under existing bank credit facilities.

 

In June 2006, we closed a $50,000 three-year term loan with a bank.  The term loan allows us to borrow at a floating rate with a lower borrowing margin than our revolving credit facility.  The term loan also provides us with two one-year options to extend the term at our discretion.  In August 2008, we exercised the first one-year option to extend the term through June 2010, and in June 2009 we exercised the second one-year option to extend the term through June 2011. We used the proceeds to refinance existing debt borrowed under the revolving credit facility.

 

In April 2006, we closed a private placement transaction pursuant to which we issued $150,000 of ten-year notes to two highly rated insurance companies at a fixed rate of 5.55%.  We used the proceeds to refinance existing debt of $150,000 drawn under a short term credit agreement with a bank in January 2006.

 

In January 2006, we closed a private placement transaction pursuant to which our Japanese subsidiary issued 34,395,000 Japanese Yen seven-year debt (equal to $300,000 at date of issuance) to several highly rated insurance companies at a fixed rate of 1.70%.  We used the proceeds to refinance existing debt in Japan.

 

Our financing arrangements provide for certain covenants and events of default customary for similar instruments, including in the case of our main bank arrangements, the private placement transactions, and the term loan, covenants to maintain specific ratios of consolidated total indebtedness to EBITDA and of EBITDA to certain fixed charges.  At September 30, 2009, we were in compliance with these financial debt covenants.

 

Severance, Impairment and Other Charges

 

In response to accelerating healthcare marketplace dynamics compounded by a sustained economic downturn, during the third quarter of 2009, we committed to a streamlining program (the “Plan”) designed to eliminate approximately 850 positions in all areas of our business and in all regions in which we operate; however, the majority of actions are planned for our Europe, Middle East and Africa (“EMEA”) region. As a result of our Plan to reduce and consolidate the number of operating units, the Plan further includes charges for certain real estate lease impairments along with related accelerated depreciation.

 

46



Table of Contents

 

During the third quarter of 2009 we recorded $104,301 in Severance, impairment and other charges and $2,024 in accelerated Depreciation and other amortization.

 

The severance benefits were calculated pursuant to the terms of established employee protection plans, in accordance with local statutory minimum requirements or individual employee contracts, as applicable.

 

The actions under the Plan were intended to: 1) streamline our EMEA region organization, including right-sizing the headquarters function, reducing and consolidating the number of operating units across the region, and improving the productivity of production and development activities; 2) leverage the foundational investments in process improvements we have made to reduce costs and improve productivity in our Sales, Finance, Human Resources and Customer Delivery and Development organizations; 3) reduce capacity and align the size of the Sales and Management Consulting teams in areas of reduced client demand; and 4) continue to build and invest in high-value, strategic growth areas, which include extending our capabilities in specialty and patient-centered insights, in serving payers and governments, and in emerging markets for pharmaceuticals.

 

We currently estimate that the total charge under the Plan will be in the range of $110,000 to $112,000 in 2009 for severance, impairment and other charges and accelerated depreciation and amortization. The balance is expected to be recorded during the fourth quarter of 2009 as we exit certain real estate facilities. The cash portion is estimated to be in the range of $106,000 to $108,000 and will be funded from cash generated from operations. Employee termination actions under the Plan are expected to be completed by the end of the third quarter of 2010.

 

 

 

Severance

 

Facility

 

Non-Cash

 

Currency

 

 

 

 

 

Related

 

Exit

 

Compensation

 

Translation

 

 

 

 

 

Reserves

 

Charges

 

Charges

 

Adjustments

 

Total

 

Charge at August 31, 2009

 

$

100,653

 

$

2,610

 

$

1,038

 

$

 

$

104,301

 

2009 utilization

 

(1,097

)

 

(1,038

)

 

(2,135

)

Currency translation adjustments

 

 

 

 

1,240

 

1,240

 

Balance at September 30, 2009

 

$

99,556

 

$

2,610

 

$

 

$

1,240

 

$

103,406

 

 

We currently expect that cash outlays will be applied against the $103,406 balance remaining in the 2009 third quarter charge at September 30, 2009 as follows:

 

Year Ended December 31,

 

Outlays

 

2009

 

$

23,308

 

2010

 

76,306

 

2011

 

1,744

 

2012

 

361

 

2013

 

268

 

Thereafter

 

1,419

 

Total

 

$

103,406

 

 

47



Table of Contents

 

During the second quarter of 2009, we recorded $25,428 in charges as a component of operating income.  Of this amount, $17,210 related to non-cash impairment charges for the write-down of certain capitalized software assets to their net realizable values in our Americas and EMEA regions.  The write-downs were the result of the regular review of our capitalized software assets.  The remaining $8,218 was for supplier contract-related charges for which we will not realize any future economic benefit.

 

During the fourth quarter of 2008, we recorded $9,408 of non-cash impairment charges as a component of operating income related to the write-off of certain capitalized software assets in our EMEA and Asia Pacific regions.  This was the result of the discontinuation of certain IMS products at the end of 2008.

 

During the fourth quarter of 2007, we committed to a restructuring plan designed to eliminate approximately 1,070 positions worldwide in production and development, sales, marketing, consulting and services and administration.  The plan also included the write-down of two impaired computer software assets and related contract payments to be incurred with no future economic benefit based on our decision to abandon certain products in our EMEA region.  As a result, we recorded $88,690 of Severance, impairment and other charges as a component of operating income in the fourth quarter of 2007.  The severance benefits were calculated pursuant to the terms of established employee protection plans, in accordance with local statutory minimum requirements or individual employee contracts, as applicable.

 

These charges were designed to strengthen client-facing operations worldwide, increase our operating efficiencies and streamline our cost structure.  Some of the initiatives included in this plan are designed to better align our resources to help clients manage for change in a challenging climate.

 

The severance and contract payments portion of the charge was approximately $75,043 and will all be settled in cash. Termination actions under the plan have been completed.

 

 

 

Severance

 

Contract

 

Asset

 

Currency

 

 

 

 

 

Related

 

Related

 

Write-

 

Translation

 

 

 

 

 

Reserves

 

Reserves

 

Downs

 

Adjustments

 

Total

 

Charge at December 31, 2007

 

$

71,583

 

$

3,460

 

$

13,647

 

$

 

$

88,690

 

2007 utilization

 

 

 

(13,647

)

 

(13,647

)

2008 utilization

 

(48,645

)

(2,150

)

 

 

(50,795

)

2009 utilization

 

(15,859

)

(817

)

 

 

(16,676

)

Currency translation adjustments

 

 

 

 

(1,806

)

(1,806

)

Balance at September 30, 2009

 

$

7,079

 

$

493

 

$

 

$

(1,806

)

$

5,766

 

 

We currently expect that cash outlays will be applied against the $5,766 balance remaining in the 2007 fourth quarter charge at September 30, 2009 as follows:

 

Year Ended December 31,

 

Outlays

 

2009

 

$

4,914

 

2010

 

717

 

2011

 

135

 

Total

 

$

5,766

 

 

48



Table of Contents

 

Recently Issued Accounting Standards

 

In June 2009, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance codifying generally accepted accounting principles in the U.S. (“GAAP”).  This guidance was effective for financial statements issued for interim and annual periods ending after September 15, 2009.  The adoption of this authoritative guidance did not have a material impact on our financial results.

 

In September 2006, the FASB issued authoritative guidance defining fair value, establishing a framework for measuring fair value under GAAP, and expanding disclosures about fair value measurements. This guidance was effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years.  The adoption of this authoritative guidance did not have a material impact on our financial results.  In February 2008, the FASB issued authoritative guidance which delayed the effective date of its previously issued fair value guidance for one year for certain non-financial assets and liabilities and removed certain leasing transactions from its scope.  The adoption of this authoritative guidance did not have a material impact on our financial results.

 

In December 2008, the FASB issued authoritative guidance on an employer’s disclosures about plan assets of a defined benefit pension or other postretirement plan.  This guidance is effective for fiscal years ending after December 15, 2009, with earlier application permitted. Upon initial application, the provisions of this guidance are not required for earlier periods that are presented for comparative purposes.  We are currently evaluating the new disclosure requirements under this authoritative guidance.

 

In April 2009, the FASB issued authoritative guidance on determining fair values when there is no active market or where the price inputs being used represent distressed sales.  It also reaffirmed what previous guidance had stated is the objective of fair value measurement—to reflect how much an asset would be sold for in an orderly transaction (as opposed to a distressed or forced transaction) at the date of the financial statements under current market conditions.  This guidance was effective for interim and annual periods ending after September 15, 2009.  The adoption of this authoritative guidance did not have a material impact on our financial results.

 

In April 2009, the FASB issued authoritative guidance which required disclosures about fair value of financial instruments for interim reporting periods of publicly traded companies as well as in annual financial statements. This standard also required those disclosures in summarized financial information at interim reporting periods.  This guidance was effective for interim reporting periods ending after September 15, 2009.  The adoption of this authoritative guidance did not have a material impact on our financial results.

 

In May 2009, the FASB issued authoritative guidance establishing general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued or are available to be issued.  This guidance was effective for interim or annual financial periods ending after September, 15, 2009.  The adoption of this authoritative guidance did not have a material impact on our financial results.

 

In June 2009, the FASB issued authoritative guidance eliminating the concept of qualifying special-purpose entities (“QSPEs”), changing the requirements for derecognizing financial assets and requiring additional disclosures about transfers of financial assets, including securitization transactions, and an

 

49



Table of Contents

 

entity’s continuing involvement in and exposure to the risks related to transferred financial assets.  This guidance must be applied as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period and for interim and annual reporting periods thereafter. The adoption of this authoritative guidance is not expected to have a material impact on our financial results.

 

In June 2009, the FASB issued authoritative guidance eliminating the exemption for QSPEs, requiring a new approach for determining who should consolidate variable-interest entities (“VIEs”), and changing when it is necessary to reassess who should consolidate VIEs.  This guidance shall be effective as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter.  The adoption of this authoritative guidance is not expected to have a material impact on our financial results.

 

In October 2009, the FASB issued authoritative guidance revising the current accounting treatment to specifically address how to determine whether an arrangement involving multiple deliverables contains more than one unit of accounting. This guidance is applicable to revenue arrangements entered into or materially modified during the company’s first fiscal year that begins after June 15, 2010. The guidance may be applied either prospectively from the beginning of the fiscal year for new or materially modified arrangements or retrospectively. We are currently evaluating this authoritative guidance to determine any potential impact that it may have on our financial results.

 

In October 2009, the FASB issued authoritative guidance changing the accounting model for revenue arrangements that include both tangible products and software elements. Tangible products containing software components and non-software components that function together to deliver the tangible product’s essential functionality, are no longer within the scope of the software revenue guidance. This guidance is applicable to revenue arrangements entered into or materially modified during the company’s first fiscal year that begins after June 15, 2010. The guidance may be applied either prospectively from the beginning of the fiscal year for new or materially modified arrangements or retrospectively. We are currently evaluating this authoritative guidance to determine any potential impact that it may have on our financial results.

 

Reconciliation of U.S. GAAP Measures to Non-GAAP Measures (a)

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

 

2009

 

2008

 

2009

 

2008

 

Selling and administrative expenses

 

$

166,885

 

$

161,878

 

$

490,211

 

$

493,010

 

Non-GAAP adjustment

 

 

(3,748

)(b)

 

(3,748

)(b)

Non-GAAP Selling and administrative expenses

 

$

166,885

 

$

158,130

 

$

490,211

 

$

489,262

 

 

 

 

 

 

 

 

 

 

 

Operating (Loss) Income

 

$

(5,544

)

$

123,976

 

$

164,608

 

$

371,735

 

Non-GAAP adjustment

 

 

3,748

(b)

 

3,748

(b)

Non-GAAP adjustment

 

2,024

(c)

 

2,024

(c)

 

Non-GAAP adjustment

 

104,301

(c)

 

104,301

(c)

 

Non-GAAP adjustment

 

 

 

25,428

(d)

 

Non-GAAP Operating Income

 

$

100,781

 

$

127,724

 

$

296,361

 

$

375,483

 

 

50



Table of Contents

 


(a)          “Non-GAAP” measures differ from “U.S. GAAP” measures for each year presented by amounts that are detailed above.  Non-GAAP measures are used by management for the purposes of global business decision-making, including developing budgets and managing expenditures.  Non-GAAP measures exclude certain U.S. GAAP measures to the extent that management believes exclusion will facilitate comparisons across periods and more clearly indicate trends.  Although we disclose Non-GAAP measures in order to give investors a view of our business as seen by management, these Non-GAAP measures are not prepared specifically for investors, are not prepared under a comprehensive set of accounting rules, and are not a replacement for the more comprehensive information for investors included in our U.S. GAAP financial statements.  Our Non-GAAP measures differ in significant respects from U.S. GAAP and are likely to differ from the Non-GAAP measures used by other companies.

 

(b)         Represents expense incurred of $3,748 recorded in 2008 related to our Government Solutions subsidiary (see Note 7 to our Condensed Consolidated Financial Statements (Unaudited)). This subsidiary had discovered potential noncompliance with various contract clauses and requirements under its General Services Administration Contract which was awarded in 2002 to its predecessor company, Synchronous Knowledge Inc. (Synchronous Knowledge Inc. was acquired by IMS in May 2005).  Upon discovery of the potential noncompliance, we began remediation efforts, promptly disclosed the potential noncompliance to the U.S. government, and were accepted into the Department of Defense Voluntary Disclosure Program.  We filed our Voluntary Disclosure Program Report (“Disclosure Report”) on August 29, 2008.  Based on our findings as disclosed in the Disclosure Report, we recorded a reserve of approximately $3,748 for this matter in the third quarter of 2008.  We are currently unable to determine the outcome of this matter pending the resolution of the Voluntary Disclosure Program process and our ultimate liability arising from this matter could exceed our current reserve.  For geographical reporting purposes, this subsidiary is included in our Americas region.

 

(c)          Represents $104,301 of severance, impairment and other charges recorded in the third quarter of 2009 for employee termination benefits and facility exit costs as a result of the streamlining program we announced in July 2009 in response to accelerating healthcare marketplace dynamics compounded by a sustained economic downturn.  Additionally, we recorded $2,024 of accelerated depreciation and amortization charges primarily related to exited facilities which are included in Depreciation and other amortization.  See Note 15 to our Condensed Consolidated Financial Statements (Unaudited).  Severance, impairment and other charges were also recorded in 2000, 2001, 2003, 2004 and 2007 and there can be no assurances that such charges will not be recorded in the future.

 

(d)         Represents $25,428 of impairment and other charges record in the second quarter of 2009 for supplier contract-related charges to be incurred with no future economic benefit and the write-down of certain capitalized software assets to their net realizable values (see Note 15 to our Condensed Consolidated Financial Statements (Unaudited)). Severance, impairment and other charges were also recorded in 2000, 2001, 2003, 2004, and 2007 and there can be no assurances that such charges will not be recorded in the future.

 

51



Table of Contents

 

Forward-Looking Statements and Risk Factors

 

This Quarterly Report on Form 10-Q, as well as information included in oral statements or other written statements made or to be made by us, contain statements that, in our opinion, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  The words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “likely,” “project,” “estimate,” “will,” “may,” “should,” “future,” “predicts,” “potential,” “continue” and similar expressions identify these forward-looking statements, which appear in a number of places in this Quarterly Report on Form 10-Q and include, but are not limited to, all statements relating to plans for future growth and other business development activities as well as capital expenditures, financing sources, dividends and the effects of regulation and competition, foreign currency conversion and all other statements regarding our intent, plans, beliefs or expectations or those of our directors or officers.  Investors are cautioned that such forward-looking statements are not assurances for future performance or events and involve risks and uncertainties that could cause actual results and developments to differ materially from those covered in such forward-looking statements.  These risks and uncertainties include, but are not limited to:

 

·                          uncertainties associated with the outcome of our exploration of strategic alternatives discussed in Note 17 to our Condensed Consolidated Financial Statements (Unaudited);

 

·                          risks associated with operating on a global basis, including fluctuations in the value of foreign currencies relative to the U.S. dollar, and the ability to successfully hedge such risks—we derived approximately 64% of our operating revenue in 2008 from non-U.S. operations;

 

·                          deterioration in economic conditions, particularly in the pharmaceutical, healthcare or other industries in which our customers operate;

 

·                          regulatory, legislative and enforcement initiatives to which we are or may become subject relating particularly to tax and to medical privacy and the collection and dissemination of data and, specifically, non-patient identifiable information, e.g., prescriber identifiable information, or to the process of anonymizing data;

 

·                          the imposition of additional restrictions on our use of or access to data, or the refusal by data suppliers to provide data to us;

 

·                          uncertainties associated with completion of our restructuring plans discussed in Note 15 to our Condensed Consolidated Financial Statements (Unaudited) and under “Severance, Impairment and Other Charges” in Part I. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations, and the impact of the restructuring activities on our business and financial results, including the timing of the activities and the associated costs and the ability to achieve projected cost savings;

 

·                          conditions in the securities markets that may affect the value or liquidity of portfolio investments; and management’s estimates of lives of assets, recoverability of assets, fair market value, estimates of liabilities and accrued income tax benefits and liabilities;

 

·                          to the extent unforeseen cash needs arise, the ability to obtain financing on favorable terms, or at all during adverse credit market conditions;

 

52



Table of Contents

 

·                          to the extent we seek growth through acquisitions, alliances or joint ventures, the ability to identify, consummate and integrate acquisitions, alliances and joint ventures on satisfactory terms;

 

·                          our ability to develop new or advanced technologies, including sophisticated information systems, software and other technology used to deliver our products and services and to do so on a timely and cost-effective basis, and the exposure to the risk of obsolescence or incompatibility of these technologies with those of our customers or suppliers; our ability to maintain effective security measures for our computer and communications systems; and failures or delays in the operation of our computer or communications systems;

 

·                          consolidation in the pharmaceutical industry and the other industries in which our customers operate;

 

·                          our ability to successfully maintain historic effective tax rates;

 

·                          our ability to maintain and defend our intellectual property rights in jurisdictions around the world;

 

·                          competition, particularly in the markets for pharmaceutical information and consulting and services;

 

·                          regulatory, legislative and enforcement initiatives to which our customers in the pharmaceutical industry are or may become subject restricting the prices that may be charged for prescription or other pharmaceutical products or the manner in which such products may be marketed or sold; and

 

·                              terrorist activity, epidemics, credit market disruptions or other conditions that could disrupt commerce, the threat of any such conditions, and responses to and results of such conditions and threats, including but not limited to effects, domestically and/or internationally, on us, our personnel and facilities, our customers and suppliers, financial markets and general economic conditions.

 

Consequently, all of the forward-looking statements we make in this document are qualified by the information contained herein, including, but not limited to, the information contained under this heading, “Risk Factors” and our Condensed Consolidated Financial Statements (Unaudited) and notes thereto for the three and nine months ended September 30, 2009 and by the material set forth under the headings “Business” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2008.  We are under no obligation to publicly release any revision to any forward-looking statement contained or incorporated herein to reflect any future events or occurrences.

 

53



Table of Contents

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

 

There has been no significant change in our exposure to market risk during the three and nine months ended September 30, 2009.  For a discussion of our exposure to market risk, refer to Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in our 2008 Annual Report on Form 10-K.

 

Item 4. Controls and Procedures

 

(a)          Evaluation of Disclosure Controls and Procedures

 

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits to the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

 

The Company’s Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-14c and 15d-14c under the Exchange Act) as of September 30, 2009 (the “Evaluation Date”). Based on such evaluation, such officers have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

(b)         Changes in Internal Control over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

54



Table of Contents

 

PART II.  OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Information in response to this Item is incorporated by reference to the information set forth in “Note 7. Contingencies” in the Notes to the Condensed Consolidated Financial Statements (Unaudited) included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

 

Item 1A. Risk Factors

 

There have been no material changes to the risk factors disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, except as follows:

 

Law restricting the use of information may restrict our product and service offerings.

 

We provide several product and service offerings to clients in the U.S. that involve the license, use and transfer of prescriber-identifiable information for commercial purposes.  New Hampshire, Vermont and Maine have passed laws placing certain restrictions on the license, use or transfer of such information for commercial purposes.  We challenged all three laws in Federal court, asking the courts to declare these laws unconstitutional.

 

·                  With respect to the New Hampshire law, the Federal District Court in Concord, New Hampshire ruled on April 30, 2007 that the law violated the First Amendment and was therefore unconstitutional and enjoined its enforcement.  However, that decision was overturned by the U.S. Court of Appeals for the First Circuit, which declared the law constitutional. The appeals court vacated the lower court’s injunction and the New Hampshire statute became effective on February 9, 2009.  On March 27, 2009, we filed a petition for certiorari to the U.S. Supreme Court asking that the Supreme Court review the appeals court’s decision in this matter.  On June 29, 2009, the Supreme Court announced that it would not hear the case. We have modified our offerings and believe we are operating in compliance with the New Hampshire law.

 

·                  With respect to the Maine law, the Federal District Court in Bangor, Maine issued a preliminary injunction on December 21, 2007, prohibiting enforcement of the Maine law.  The Maine Attorney General has appealed the preliminary injunction ruling to the U.S. Court of Appeals for the First Circuit.

 

·                  With respect to the Vermont law, the Federal District Court in Brattleboro, Vermont held a full trial ending on August 1, 2008. On April 23, 2009 the court issued its decision upholding the Vermont law. We appealed the district court’s decision to the U.S. Court of Appeals for the Second Circuit. The data restrictions in the Vermont law became effective on July 1, 2009.  We have modified our offerings and believe we are operating in compliance with the Vermont law.

 

These three states collectively represent approximately one percent of prescription activity in the United States, so the potential financial impact of these laws on our business, financial condition and results of operations is not expected to be material.  However, there have been a significant number of state legislative initiatives over the past several years that seek to impose similar restrictions on the commercial use of prescriber-identifiable information. During 2009, these initiatives were introduced in 23 states. They were unsuccessful in 20 states and no further legislative action is expected in the

 

55



Table of Contents

 

remaining three states. We are unable to predict whether and in what form these initiatives will continue or whether additional states or the Federal government will seek to enact similar or more restrictive legislation or regulation of such information.  In addition, while we will continue to seek to adapt our products and service offerings (including consulting and services offerings) to comply with the requirements of these laws, there can be no assurance that our efforts to adapt our offerings will be successful and provide the same financial contribution to us.  There can also be no assurance that these kinds of legislative initiatives will not adversely affect our ability to generate or assemble data or to develop or market current or future offerings, which could, over time, result in a material adverse impact on our revenues, net income and earnings per share.

 

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

 

Period

 

Total
Number of
Shares
Purchased

 

Average
Price
Paid per
Share

 

Total Number of
Shares Purchased
Under Publicly
Announced
Programs

 

Maximum Number of
Shares that May Yet Be
Purchased Under the
Programs (1)

 

 

 

 

 

 

 

 

 

 

 

July 1-31, 2009

 

 

 

 

9,505,300

 

August 1-31, 2009

 

 

 

 

9,505,300

 

September 1-30, 2009

 

 

 

 

9,505,300

 

Total

 

 

 

 

9,505,300

 

 


(1)                    In December 2007, our Board of Directors authorized a stock repurchase program to buy up to 20,000,000 shares. As of September 30, 2009, 9,505,300 shares remained available for repurchase under the December 2007 program. Unless terminated earlier by resolution of our Board of Directors, this program will expire when we have repurchased all shares authorized for repurchase thereunder.  See Note 12 of our Notes to Condensed Consolidated Financial Statements (Unaudited) for further details.

 

56



Table of Contents

 

Item 6.  Exhibits

 

(a)       Exhibits

 

Exhibit
Number

 

Description of Exhibits

 

 

 

31.1

 

CEO 302 Certification pursuant to Rule 13a-14(a)/15d-14(a).

 

 

 

31.2

 

CFO 302 Certification pursuant to Rule 13a-14(a)/15d-14(a).

 

 

 

32.1

 

Joint CEO/CFO Certification Required Under Section 906 of the Sarbanes-Oxley Act of 2002.

 

57



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

IMS Health Incorporated

 

 

 

 

 

 

 

By:

/s/ Leslye G. Katz

Date: October 30, 2009

 

Leslye G. Katz

 

 

Senior Vice President and Chief Financial Officer

 

 

(principal financial officer)

 

 

 

 

 

 

 

 

/s/ Harshan Bhangdia

Date: October 30, 2009

 

Harshan Bhangdia

 

 

Vice President, Controller

 

 

(principal accounting officer)

 

58



Table of Contents

 

EXHIBIT INDEX

 

Exhibit
Number

 

Description of Exhibits

 

 

 

31.1

 

CEO 302 Certification pursuant to Rule 13a-14(a)/15d-14(a).

 

 

 

31.2

 

CFO 302 Certification pursuant to Rule 13a-14(a)/15d-14(a).

 

 

 

32.1

 

Joint CEO/CFO Certification Required Under Section 906 of the Sarbanes-Oxley Act of 2002.

 

59